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ABSTRACT 
 
Natural products have historically been the most productive source of leads for 
the development of drugs. Thanks to the chemical methodologies of natural 
products, a vast array of bioactive secondary metabolites from terrestrial and 
marine sources has been discovered. Many of these natural products became 
current drug candidates. Therefore, the research of new biologically active 
compounds through structure elucidation and biological tests is the central 
issue of these studies. My research is placed in this field and it has been mainly 
devoted to the discovery and to the chemical and pharmacological investigation 
of new bioactive natural products as “lead compounds” in the antitumor and 
antimalarial activities area. My work, described in this PhD thesis, was 
organized in two different topics: i) isolation and structural characterization of 
bioactive secondary metabolites from marine invertebrates, ii) synthesis of 
thiazinoquinones derivatives endowed with cytotoxic and antiplasmodial 
activities from marine natural metabolites. The achievement of my research 
project required isolation and extraction procedures. The chemical 
characterization of the isolated compounds has been performed through an 
extensive spectroscopic analysis (UV, IR, ECD, 1D and 2D NMR) together 
with mass spectrometry, computational and electrochemistry methods. I have 
also used synthetic methods both for the chemical derivatization of the isolated 
molecules and for the preparation of analogues on the simplified model of 
natural molecules. 
During the course of my PhD research, whose results are reported in the 
following thesis, I have been dealing with the extraction and the chemical re-
investigation of a new collection of the Mediterranean ascidian Phallusia 
fumigata. This analysis led to the isolation of one sulfated sterol, 
phallusiasterol C, which is a possible modulator of the PXR nuclear receptor. 
Morover, I have been strongly involved in completing the stereochemistry 
assignment of phosphoeleganin, a complex acyclic marine natural product, 
isolated previously from the Mediterranean ascidian Sidnyum elegans. 
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In addition, the electrochemical response of four natural cytotoxic 
thiazinoquinones, beforehand isolated and characterized from Aplidium 
species, has been investigated, in order to clarify the mechanism of action 
which is the basis of their cytotoxicity. The research for new antiplasmodial 
hits is another main topic of my PhD activity discussed in this thesis. 
Previously, having identified the thiazinoquinone nucleus as new active 
chemiotype against P. falciparum, my research started from the development 
of two new series of methoxy and amide derivatives inspired by two marine 
metabolites isolated from the Mediterranean ascidian Aplidium conicum. 
Recently, in order to refine this pharmacophore model and improve the 
pharmacokinetic and pharmacodynamic properties, I have performed a rational 
design and synthesis of new modified analogues with simplified side chains 
and different substituents. In collaboration with the Department of Biomedical, 
Surgical and Dental sciences (University of Milan), the synthetic analogues of 
natural quinones have been tested for their in vitro antiplasmodial activity 
against both chloroquine (CQ)-sensitive (D10) and -resistant (W2) strains of P. 
falciparum, although some of them were strongly cytotoxic. Some of the 
synthetic derivatives showed significant antiplasmodial activity together with 
some important structural requirements. Additionally, in order to rationalize 
the structure-activity relationships (SARs), an integrated approach based on 
computational and electrochemistry studies was performed. These studies were 
carried out by a further collaborating external research group. The above 
results clearly evidence that quinone natural products represent an excellent 
source of novel “drug-like” small molecules for drug discovery in antimalarial 
research.  
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ITALIAN ABSTRACT 
 
Le sostanze naturali sono da sempre una delle più ricche fonti di composti 
guida per la scoperta di farmaci. Grazie agli studi chimichi sui prodotti naturali, 
è stata scoperta una vasta gamma di metaboliti secondari bioattivi da fonti 
terrestri e marine. Molti di questi prodotti naturali sono divenuti attualmente 
drug candidates. Pertanto, il problema centrale di questi studi resta la ricerca di 
nuovi composti biologicamente attivi attraverso la determinazione 
stereostrutturale e i test biologici. 
La mia ricerca si colloca in questo ambito e si è incentrata sulla scoperta e sullo 
studio chimico e farmacologico di nuovi prodotti naturali bioattivi, come nuovi 
potenziali "leads" per la terapia antitumorale e antimalarica. 
Il mio lavoro, descritto in questa tesi di Dottorato, è stato organizzato in due 
differenti argomenti: i) isolamento e caratterizzazione strutturale di metaboliti 
secondari bioattivi da invertebrati marini, ii) sintesi di derivati tiazinochinonici 
con attività citotossica ed antiplasmodio a partire da lead compounds di origine 
naturale. 
La realizzazione del mio progetto di ricerca ha richiesto l’utilizzo di diverse 
metodiche di estrazione e di isolamento. La caratterizzazione chimica dei 
composti isolati è stata effettuata attraverso un'ampia analisi spettroscopica 
(UV, IR, ECD e NMR mono- e bi-dimensionale) insieme a metodi 
spettrometria di massa, studi computazionali ed elettrochimici. Sono state 
utilizzate anche metodiche sintetiche sia per la derivatizzazione chimica delle 
molecole isolate che per la preparazione di analoghi semplificati sul modello di 
molecole naturali. 
Nel corso dell’attività di ricerca svolta durante il corso di Dottorato, i cui 
risultati sono riportati nella seguente tesi, mi sono occupata dell’estrazione e 
dell’analisi chimica ex novo dell’ascidia del Mar Mediteranneo Phallusia 
fumigata. Questa analisi ha portato all'isolamento di uno sterolo solfatato, 
phallusiasterolo C, un possibile modulatore del recettore nucleare PXR. 
La mia attività di ricerca si è incentrata anche sul completamento della 
determinazione della configurazione assoluta della fosfoeleganina, un prodotto 
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naturale aciclico complesso, isolato in precedenza dall’ascidia del Mar 
Mediteranneo Sidnyum elegans. 
Inoltre, sono stati eseguiti studi elettrochimici e computazionali su quattro 
tiazinochinoni citotossici naturali, precedentemente isolati e caratterizzati 
dall’ascidia Aplidium conicum, con l’intento di chiarire il meccanismo d’azione 
che è alla base della loro citotossicità.   
La ricerca di nuovi hits antimalarici è un altro tema principale della mia attività 
di dottorato, discussa in questa tesi. Precedentemente, avendo individuato il 
nucleo tiazinochinonico come nuovo chemiotipo attivo contro il Plasmodium 
falciparum, il punto di partenza della mia ricerca è stato lo sviluppo di due 
nuove serie di metossi e ammido derivati, progettati sul modello di due 
metaboliti marini isolati dall’ascidia Aplidium conicum. Recentemente, al fine 
di perfezionare questo modello farmacoforico e di migliorarne le proprietà 
farmacocinetiche e farmacodinamiche, ho effettuato la sintesi di nuovi analoghi 
modificati con catene laterali semplificate e diversi sostituenti.  
In collaborazione con il Dipartimento di Scienze Biomediche Chirurgiche e 
Odontoiatriche dell’Università di Milano, gli analoghi sintetici sono stati testati 
per valutare la loro attività antiplasmodio, in vitro, sui ceppi di Plasmodium 
falciparum D10 (clorochina-sensibile) e W2 (clorochina-resistente). Alcuni di 
questi composti sono risultati fortemente citotossici, mente altri hanno esibito 
una significativa attività antiplasmodio insieme ad alcuni requisiti strutturali 
importanti. 
Inoltre, per comprendere le relazioni struttura-attività (SAR), questi composti 
sono stati sottoposti a studi computazionali ed elettrochimici, effettuati 
avvalendoci della collaborazione di gruppi di ricerca esterni.  
L’insieme dei risultati ottenuti evidenziano chiaramente che i chinoni naturali 
rappresentano un'ottima fonte di nuove “drug-like” small molecules per lo 
sviluppo di nuovi farmaci antimalarici. 
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INTRODUCTION 
 
The constant need for the discovery of more effective and less expensive drugs 
is legitimated by several crucial factors, such as exisisting diseases without 
cure, drug resistance, emergence of new or mutated viruses, and very 
expensive drugs.1 Nature represents a fascinating resource of new bioactive 
molecules and the study of these metabolites has been up to now the most 
successful way to the drug discovery. The discovery of natural products helped 
numerous life saving medicines and medical breakthroughs, particularly in the 
treatment of cancer, infectious diseases, hypercholesterolemia and 
immunological disorders.  
Well-known examples of widely used natural products are lovastatin 
(anticholesterolemic agent), erythromycin (antibiotic), cyclosporine A, 
amphotericin B (fungicidal agent), and FK506 (immunosuppressive agents).2,3 
In addition, according to an article written by the National Cancer Institute 
(NCI) scientists, the new molecules, recently introduced as anticancer drugs, 
were completely inspired by natural products and their derivatives.4 The 
largely unexplored marine world, which probably harbors the greatest 
biodiversity, may be the biggest resource to discover novel structures with new 
mechanisms of action that cover biologically relevant activities. However, it 
issues several challenges, including the access to the marine environment and 
the chemical and biological characterizations of the promising natural products, 
which are often collected in a very minute amount. Consequently, updates in 
technologies, also in sampling methods, new synthetic approaches, 
biotechnology, and nanoscale NMR for structure determination are all crucial 
to the success of marine natural products as drug leads. Until a few years ago, 
more than a micromole of a compound was essential to assign completely its 
                                                          
1 Strobel, G. D. Mol. Biol. Rev., 2003, 67, 491. 
2 O’Neill, M.; J.A. Lewis in Human Medicinal agents from Plant. Kinghorn, A. D., Balandrin, 
M. F., Eds.; ACS Symposium Series 534; American Chemical Society: Washington, D. C., 
1993, 48. 
3 Cragg, G.M.; Newmann, D. J.; Snader K.M. J. Nat. Prod., 1997, 60, 52. 
4 Newman, D. J. C., G. M.; Snader, K. M. J. Nat. Prod., 2003, 66, 1022. 
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structure. Recent advances, expecially in NMR structure determination 
methodologies, have changed this obligation and now it is possible to analise 
the product on a nanomole or even picomole scale.5 
In this thesis, the results obtained during my PhD research program, are 
illustrated. My research was indeed grounded in the field of natural products 
chemistry and mainly aimed to the discovery of new bioactive natural 
compounds, useful as models for the development of new medicinal drugs. The 
research work was divided into two different parts, the isolation and 
pharmacological characterization of new bioactive molecules from terrestrial 
and marine organisms and the optimization of the studied natural leads through 
de novo synthesis and/or structural modifications. Our efforts were directed 
towards the design and the synthesis of simplified analogues of the natural 
products. Through active collaborations with selected national and foreign 
research groups, both natural and synthetic compounds selected collections 
have been submitted to pharmacological tests plus an original combination of 
electrochemical and computational studies in order to analise the structure-
activity relationships. The whole of my studies led to the isolation and 
identification of several bioactive molecules, with different structures, ranging 
from simple linear polyfunctionalized alkyl chains to complex polycyclic 
frameworks, and contributed to enlarge the chemical diversity generated into 
natural products of marine origin. 
On the other hand, the synthetic studies performed using already known marine 
natural compounds led to the identification of derivatives with significant 
antiplasmodial activity and also highlighted some structural requirements 
critical for both the antiplasmodial and the cytotoxic activities. My research 
strongly highlighted the potential of natural products to qualify as lead 
structures for medicinal chemistry, affording analogues easier to synthesize and 
with better bioactivity.  
 
 
                                                          
5 Montaser, R; Luesch H. Future Med Chem., 2011, 12,1475-89 
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CHAPTER 1 
THE NATURAL PRODUCTS IN DRUG DISCOVERY 
 
1.1. The natural products as a source of therapeutic agents and of 
structural diversity  
Natural products remain a foundamental component in the search and 
development for innovative, safe and less expensive medicaments. Actually, in 
developed nations, the majority of all prescribed drugs derive from natural 
products, whose only available sources are animals, marine, plants, and 
microorganisms. The utility of natural products in the prevention and treatment 
of human diseases follows three criteria: I) the introduction of new natural 
chemical molecules of a wide structural diversity, used as templates for semi 
synthetic and total synthetic modification; II) the number of diseases prevented 
or treated by them; and III) their frequency of use in the treatment and 
prevention of human diseases. Natural products are rich sources of lead 
compounds suitable for further modifications during drug development. A 
potential explanation of the natural products success is their classification as 
so-called privileged structures. This concept is based on the fact that these 
chemical entities are produced by living organisms (in particular the secondary 
metabolites) and they have evolved throughout millenniums, getting a specific 
biological activity in comparison to the “randomly” developed synthetic 
chemicals. In spite of the great potential, only a small part of globe’s living 
species has ever been tested for any activity.6 
One key point of natural products is, thus, their great structural and chemical 
diversity. The idea of creating drug leads embraces the concept of achieving 
high molecular diversity within the boundaries of reasonable DRUG-LIKE 
properties.7,8 They provided, also, design principles for the development of 
combinatorial library. In chemical genetics/genomics, the access to collections 
                                                          
6 Chin, Y. W., Balunas, M. J., Chai, H. B., King- horn, A. D. The American Association of 
Pharmaceutical Scientists Journal., 2006, 8, 239-242. 
7 Ajay, W. P. W., Murcko, M. J. Med. Chem., 1998, 41, 3314–3324.  
8 Sadowski, J., Kubinyi, H. J. Med. Chem., 1998, 41, 3325–3329.  
 
11 
 
of structurally diverse and complex small molecules is extremely important. 
Regarding the chemical genetics/genomics, two are the major compounds 
sources: natural products (including their derivatives) and combinatorial 
chemistry libraries. Due to the developing of combinatorial chemistry, 
nowadays preparing a large number of small molecules is relatively easy. 
Additionally, because of their important biological processes, new chemical 
modulators have been identified from the screening of small molecules 
originating from combinatorial chemistry library. 9,10 
However, the traditional combinatorial libraries process, ‘one-synthesis/one-
scaffold’, generally shows limited structural diversity. 
On the other hand, natural products are known to possess an even greater 
diversity in chemical space hence producing a deep-routed impact on chemical 
biology and drug development.11,12,13 Most of the natural products produced by 
plants or microorganisms are not meant to bind to human proteins. However, 
for many years, microorganisms and plants have evolved leading to the 
production of small ligands (or natural products) for their macromolecular 
targets inside the living organisms.14 Furthermore, several human proteins 
targets contain structural domains that are similar to those which small ligands 
(or natural products) have coevolved with.15 
By means of the natural selection process, natural products possess a vast and 
unique chemical diversity and have evolved for optimal interactions with 
biological macromolecules.  
                                                          
9 Wurdak H., Zhu S., Min KH., Aimone L., Lairson LL., Watson J., Chopiuk G., Demas J., 
Charette B., Weerapana E., Cravatt BF., Cline HT., Peters EC., Zhang J., Walker JR., Wu C., 
Chang J., Tuntland T., Cho CY., Schultz PG. Proc Natl Acad Sci USA., 2010, 107, 16542–
16547. 
10 Bradner J.E., Mak R., Tanguturi S.K., Mazitschek R., Haggarty S.J., Ross K., Chang C.Y., 
Bosco J., West N., Morse E., Lin K., Shen J.P., Kwiatkowski N.P., Gheldof N., Dekker J., 
DeAngelo D.J, Carr S.A., Schreiber S.L., Golub T.R., Ebert B.L. Proc Natl Acad Sci USA., 
2010, 107, 12617–12622. 
11 Clardy J., Walsh C. Nature., 2004, 432, 829–837.  
12 Feher M., Schmidt J.M. J Chem Inf Comput Sci., 2003, 43, 218–227. 
13 Rosén J., Gottfries J., Muresan S., Backlund A., Oprea T.I. J Med Chem., 2009, 52, 1953–
1962. 
14 Firn R.D., Jones C.G. Nat Prod Rep., 2003, 20, 382–391. 
15 Bon R.S, Waldmann H. Acc Chem Res., 2010, 43, 1103–1114.  
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Indeed, another important advantage of natural products is their biological 
background. Biosynthesis of natural products includes interactions with 
modulating enzymes, and binding to other proteins, which stands for their 
actual biological function. Thus, in order to develop an effective drug, the 
ability of natural products to interact with other molecules is necessary. Most 
probably, this is a consequence of their sterically more complex structure.16 In 
addition, natural products have higher molecular weights; fewer halogen, 
nitrogen, or sulfur atoms but more oxygen atoms; and more bridgehead 
tetrahedral carbon atoms, rings, and chiral centers. 
In the past, most drugs have been discovered by identifying the active 
ingredient from traditional remedies.6 Nowadays, instead, the new approach 
includes the control of diseases and infections at the molecular and 
physiological level and to target specific entities. The drug discovery process is 
long and it involves the identification of candidates, characterization, synthesis, 
screening, and assays for therapeutic efficacy. Once a compound has shown its 
potential in these tests, the process of drug development prior to clinical trials 
begins.17 
The success of natural products is related to several disciplines such as: 
molecular and cellular biology, synthetic and analytical chemistry, 
biochemistry, and pharmacology.18 Pharmaceutical industry, in this prospect, 
should change its mindset and address itself to natural product based drug 
discovery programs.19 Infact, an integrated approach, combining different 
discovery tools and disciplines, will provide for sure the key for success in 
natural product drug discovery and development. 
 
1.2. The marine environment as a prolific source of bioactive compounds 
and chemical diversity 
Because of the structural and biological diversity of their constituents, marine 
enviroment is a unique and renewable resource for the discovering and 
                                                          
16 Lutz, M. K. Nature Biotechnology., 2003, 21, 602-604. 
17 Lahlou, M. Expert Opinion on Drug Discovery., 2007, 2, 697-705. 
18 Nisbet, L. J., Moore, M., Soejarto, D. D. Current Opinion in Biotechnology., 1997, 8, 708-
712.  
19 Mouhssen, L. Pharmacology & Pharmacy., 2013, 4, 17-31 
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development of potential new drugs and bioactive entities. The study of marine 
natural products is more complex than that of terrestrial origin compounds due 
to their difficulty in collection and identification. However, despite these 
difficulties, the marine environment is a very rich source of powerful 
compounds that have shown significant activities in anti-inflammatory, 
antitumor, allergy, analgesia, immuno-modulation, and anti-viral assays.20 
The oceans cover more than 70% of the earth’s surface and contain more than 
300,000 described species of plants and animals.21,22 
Macroscopic plants and animals have adapted to all regions of the oceans, 
including temperate, polar, and tropical areas. The activity and the number of 
natural products is directly related to the huge biodiversity of life that the 
marine environment has. The most promising marine natural products are small 
to medium molecular weight compounds produced principally by marine 
invertebrates (sponges, soft corals, tunicates) and microbes. These organisms 
live in a highly competitive and complex environment and produce a vast 
variety of toxic chemicals in order to prevent parasitism and predation. All 
marine organisms have provided a parade of very unusual novel structures; 
biogenetically, they can be included in the biosynthetic pathways used for 
terrestrial secondary metabolites, whereas, structurally, they often posses 
predominantly marine functional groups. In Particular, ascidians’ chemistry is 
characterised by the presence of nitrogenous metabolites. Thanks to the 
combined efforts of marine natural product pharmacologists and chemists, 
several promising compounds have been identified; some of them have been 
already selected as promising candidates for extended pre-clinical evaluation, 
whereas others are already at advanced stages of clinical trials. Most of these 
products are used for cancer therapy; for example, the marine alkaloid 
ecteinascidin 743 (ET-743), which is an anti-tumour compound particularly 
effective against solid tumours.19 
                                                          
20 Pomponi, SA. J Biotechnol.,1999, 70, 5–13.  
21 Newman, D.J. Cragg, G. M.; J. Nat. Prod., 2004, 67 (8), 1216–1238. 
22 Jimeno, J.M. Anticancer Drugs., 2002, 13 ,15–19. 
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On the other hand, the search of marine origin molecules has evolved relatively 
slowly, mainly because of the small available quantities of the living material. 
It is very common to isolate less than one milligram of a bioactive substance 
from one kilogram of the marine organism. However, more sensitive methods 
of NMR spectroscopy and mass spectrometry combined with advanced liquid 
chromatography techniques are currently used for identification and 
characterization of natural products. So, complex molecular structures can be 
now solved using less than one milligram of compound. Chemical 
identification of the molecules present in biological extracts is just one step of 
their full investigation; a particularly interesting aspect is the individuation of 
their real producers. The incredible potential of even a single marine organism 
to produce secondary metabolites is due to the peculiar features of the marine 
environment. The highly rich secondary metabolism of some marine 
invertebrates can be explained by the evidence that marine invertebrates 
harbour microorganisms in their tissues (in particular in the extra- and intra-
cellular spaces), such as bacteria, cyanobacteria and fungi. In some cases, 
associated microorganisms may constitute up to a 40% of the biomass. The 
possible microbial origin of bioactive molecules from marine invertebrates, 
recently highlighted new and interesting perspectives for their synthesis at 
commercial level. Isolation and cultivation of the suspected microbial 
producers either from the tissues of invertebrates or from the surrounding 
seawater could provide a more satisfying answer to the supply problem. If 
bacteria are actually the producers of bioactive metabolites of interest, 
transferring the gene clusters, responsible for the biosynthesis of the respective 
natural products, to a vector suitable for large-scale fermentation could provide 
an alternative strategy thereby avoiding the difficulties in culturing symbiotic 
bacteria. 
A fascinating example of the great variety of secondary metabolites, from 
marine sponges, can be represented by bromopyrrole alkaloids. These natural 
products, whose architectural complexity ranges from simple, achiral, 
monomeric oroidin (1, Figure 1.1) to 16-stereocenter-containing tetrameric 
stylissadines (4-5, Figure 1.2), have been isolated from different species of 
15 
 
Agelasidae, Axinellidae, Dyctionellidae and Hymeniacidonidae sponges 
families.23 These alkaloids, belonging to the outlined above sponges families, 
show a systematic recurrence which allowed to speculate their taxon-
specificity and, later on, to consider them as chemical markers for 
phylogenetically related sponges.24 The majority of these alkaloids share the 
key building block pyrrole-imidazole; oroidin (1) was the first member isolated 
from this group and it is the underlying structural motif of this alkaloids 
family.25  
On this subject, we can mention the oroidin-like linear monomers (1-3) and 
tetramers (4-5). These structures contain the skeleton of oroidin without any 
further C-C or C-N bond formation. Hymenidin (2, Figure 1.1), isolated from 
the Okinawan sponge Hymeniacidon sp.26 is the 2-debromo derivative of 
oroidin, whereas clathrodin (3), isolated from the Caribbean Sea sponge Agelas 
clathrodes27 is its 2,3-debromo derivative. 
 
 
 
 
Figure 1.1. Structures of oroidin (1), hymenidin (2), and clathrodin (3). 
 
The degree of bromination of the pyrrole moiety has been shown to affect the 
biological properties of these compounds. Both oroidin and hymenidin have 
exhibited to reduce the voltage dependent calcium elevation in PC12 cells. 
Furthermore, the potency of the tested alkaloids increases together with the 
number of bromine atoms associated to the pyrrole ring. Analogously, the 
bromination degree also affects the feeding deterrent properties, hymenidin 
                                                          
23 Forte, B., Malgesini, B., Piutti, C., Quartieri, F., Scolaro, A., Papeo, G. Mar. Drugs., 2009, 7, 
705-753. 
24 Braekman, J.C., Daloze, D., Stoller, C., Van Soest, R.W.M. Biochem. Syst. Ecol., 1992, 20, 
417-431. 
25 Garcia, E. E., Benjamin, L. E., Fryer, R. I. J. Chem. Soc. D. Chem. Commun., 1973, 78-79. 
26 Kobayashi, J., Ohizumi, Y., Nnakamura, H., Hirata, Y. Experientia., 1986, 42, 1176-1177. 
27 Morales, J. J., Rodriguez, A. D. J. Nat. Prod., 1991, 54, 629-631.  
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being less potent than oroidin.28 Oroidin, hymenidin and clathrodin showed 
marked antiserotonergic and anticholinergic activities.29,29, Clathrodin is a 
sodium channel neurotoxin, which acts by influencing the channel ionic 
conductance.30 Adversely, stylissadines (4-5) are tetrameric molecules. 
Structurally speaking, they are ether-linked dimers of massadine, they are the 
largest ones and, with their 16 stereogenic centers, they represent the most 
complex structures within the oroidin family of alkaloids so far discovered. 
They both have biological activity as antagonists of the P2X7 receptor 
involved in inflammatory diseases, however, their high molecular weight 
together with their structural complexity make them hard to develop as drugs.31 
 
 
 
 
  
 
 
 
 
 
 
Figure 1.2. Oroidin-like tetramers: stylissadines A and B (4-5). 
 
In conclusion, it is evident that marine environment will continue to be a major 
source of new drug leads, however, the effective utilization of these resources 
will require advances in technologies together with the opening of new 
frontiers in science.  
                                                          
28 Assmann, M., Zea, S., Koeck, M. J. Nat. Prod., 2001, 64, 1593-1595.23. 
29 Rosa, R. Silva, W., Escalona de Motta, G., Rodriguez, A. D., Morales, J. J., Ortiz, M. 
Experientia., 1992, 48, 885-887.  
30 Rivera Rentas, A.L., Rosa, R., Rodriguez, A. D., Escalona de Motta, G. Toxicon.,1995, 33, 
491-497. 
31 Grube, A., Köck, M. Org. Lett., 2006, 8, 4675-4678 
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CHAPTER 2 
METHODOLOGY IN ISOLATING AND CHARACTERIZING 
MARINE NATURAL PRODUCTS 
 
The collection of biological material in the marine environment as well as its 
identification involves a great number of restrictions that lead to the necessity 
of separating small quantities of mixture and of characterizing them in a non-
destructive way. 
The study of marine natural products follows different steps such as the 
isolation, purification and the structural determination of the isolated new 
compounds. 
 
2.1. Isolation procedures 
The isolation of natural products from natural sources exhibits numerous 
problems, because they may only exist in infinitesimal quantities. Therefore, a 
good selection of different techniques and approaches is required to solve this 
issue. The problem of separation and isolation of new metabolites was 
overcome with the introduction of sophisticated techniques, such as the various 
analytical and preparative chromatographic methods, enabling a successful 
procedure of purification. Normally, after biomass extraction with adequate 
solvents (like acetone, ethanol, and/or chloroform), the first step of natural 
compounds isolation, from the main extract, consists of a sequential gradient 
partition with solvents. The so gained fractions contain compounds distributed 
according to their polarity. In particular, in the case of bioactive extract, this 
process can be guided by the appropriate assay in order to localize the active 
component. Subsequently, different purification procedures can be performed, 
taking in consideration the various properties of the components of these 
fractions. Specifically, the fractions of low or medium polarity, usually 
monitored, enclose lipophilic organic compounds that can be usually separated 
by standard normal or reverse phase column chromatography and/or MPLC 
and finally HPLC to obtain the individual components. 
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Medium Pressure Liquid Chromatography (MPLC) is a liquid-solid 
chromatography, in which the liquid mobile phase is forced through the solid 
stationary phase at medium pressure. MPLC is more efficient, regarding the 
resolution, in comparison to the open-column and the flash chromatography 
methods and, in addition, the separation involves a significant gain in time. The 
solid stationary phase can be a normal phase, like silica gel, or bonded phase 
(RP-8, RP-18). The technique uses a pressure of ca. 5-40 bar and can readily 
accommodate much larger sample loads (100 mg-100 g) that are generally 
applied in other separations. Concerning the separating power, MPLC lies 
between flash chromatography and semi-preparative HPLC. 
High Performance (or High Pressure) Liquid Chromatography (HPLC) is the 
most widely used chromatographic method, employing both the normal- and 
reverse-phase. It is used in the preparative separation of samples, to “optimize” 
the isolation of natural products (optimization of the experimental conditions, 
checking of the different fractions all over the separation). However, HPLC is 
usually applied as the last step in purification processes providing pure 
compounds in high yields, and, in this regard, the quantities involved have the 
tendency to be at the lower end of the scale.  
Finally, the isolated compounds are structurally characterized and are subjected 
to pharmacological assays. 
 
2.2. Structural determination methods 
Recently, natural products chemistry has seen an exponential growth due to 
advances in isolation techniques, as well as in the synthetic and biosynthetic 
approaches and spectroscopic and chromatographic methods.  
The structural determination described in my thesis is considerably based on 
spectroscopic techniques, in particular mass spectrometry (MS) and nuclear 
magnetic resonance (NMR), and sometimes degradation methods too, coupled 
with circular dichroism (ECD) and computational methods. 
 
 
 
19 
 
2.2.1. Mass Spectrometry 
Mass Spectrometry is a destructive analytical technique, utilized to define the 
elementary formula of unknown compounds through the measurement of their 
molecular masses. Firstly, a molecule is ionized and transferred to gas phase in 
the ionisation source and then it is transported to the mass analyzer to measure 
its mass properties. In order to obtain a mass spectrum, in the ion source, must 
be generated ions in a gas-phase. They are consequently accelerated, by an 
electric field, up to they get to a particular speed and they are transferred to the 
mass analyzer, which separate different ions on the base of their mass/charge 
(m/z) ratio. The separated ions are after that measured on the detector and the 
results showed. 
Most of compounds reported in the following chapters have been analyzed by 
Electrospray Ionisation (ESI) mass spectrometry through an Orbitrap system.  
This type of technique is used to identify non-volatile molecules, directly from 
the liquid phase (Figure 2.1). The start and the end of this process can be 
verified by an electrical circuit through which the spray of liquid-charged 
droplets is driven. 
 
Figure 2.1 ESI mass spectrometry. 
At the beginning of this process, a molecule presents as an entity or complex 
charged and dissolved in a water-rich environment while at the end of it, the 
same molecule is displayed by a mass analyser as a series of multicharged ions. 
In vacuum, the biomolecular ions are then selectively examined according to 
their mass/charge ratio. Due to the electric potential of the capillary, each 
droplet of the spray carries an excess of positive or negative charge, and this 
causes wide protonation or deprotonation of the molecules of the sample, 
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developing ions. An uncharged carrier gas for example nitrogen is utilized to 
help the liquid to be nebulized and the neutral solvent in the droplets to 
evaporate. 
Orbitrap is an innovative kind of mass analyzer introduced by Makarov.32 The 
LTQ-Orbitrap combines the most advanced Ion Trap and Fourier Transform 
technologies into a single instrument with unique analytical power and 
adaptability. The instrument affords a high mass resolution, accurate mass 
determinations, and MS for routine high-throughput analysis. 
In an orbitrap, ions are injected tangentially into the electric field between the 
electrodes and captured because their electrostatic attraction to the inner 
electrode is in equilibrium with centrifugal forces. Therefore, ions cycle around 
the central electrode in rings. Additionally, the ions also move back and forth 
along the axis of the central electrode. Therefore, ions of a specific mass-to-
charge ratio move in rings that oscillate along the central spindle (Figure 2.2). 
The occurrence of these harmonic oscillations is independent of the ion 
velocity and is inversely proportional to the square root of the mass-to-charge 
ratio (m/z).  
 
Figure 2.2. Ion trajectories in an Orbitrap mass spectrometer. 
By sensing the ion oscillation similar as in the FT-MS (Fourier transform mass 
spectrometry), the trap can be utilized as a mass analyzer. Orbitraps have a 
high mass accuracy (1-2 ppm), a high resolving power (up to 200,000). Now, 
                                                          
32 Hu, Q.; Noll, R. J.; Li, H.; Makarov, A.; Hardmanand, M.; Cooks, R. G.; J. Mass Spectrom., 
2005, 40, 430–443. 
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there are two commercial LTQ-Orbitrap instruments, the Discovery and XL 
models. One of the principal differences is that the XL has a linear octopole 
collision cell (absent in the Discovery model), in which collisional activation 
and fragmentation can be achieved. Even if this feature affords additional 
versatility to MS/MS experiments, the analytical performance and fundamental 
principles of operation of the Orbitrap analyzers in both instruments are 
identical.33 
 
2.2.2. Nuclear Magnetic Resonance 
The structural determination of the isolated compounds can be carried out 
through the Nuclear Magnetic Resonance34,35,36 spectroscopy which is based on 
the reorientations of nuclear spins with respect to an applied static magnetic 
field. Furthermore, to standard 1H and 13C NMR spectra, a large use of 2D 
NMR experiments has been made during my research activity. They are 
superior to their 1D NMR counterparts both for the information on the 
connection between nuclei and for the easier assignment of nuclei resonating in 
crowded regions of the spectra (signal overlapping is much less likely in two 
dimensions than in one). 
For example, in order to establish the connectivity of the molecule through the 
identification of spins which are coupled to each other, the COSY (COrrelation 
SpectroscopY) experiments are widely used.  
Another type of the 2D NMR experiment is the HSQC (Heteronuclear Single 
Quantum Correlation) that permits to obtain a chemical shift correlation 
between directly bonded 1H-13C.  
The HMBC (Heteronuclear Multiple Bond Correlation) experiment is a 
heteronuclear two-and three-bond 1H-13C correlation experiment; its sequence 
is less efficient than HSQC because the involved 2,3JCH couplings are smaller 
(3-10Hz). Moreover, while 1JCH are all quite close to each other, 
2,3JCH can be 
                                                          
33 Perry, R. H.; Cooks, R. G.; Noll, R. J.; Mass Spectrometry Reviews., 2008, 27, 661– 69. 
34 Bax, A.; Two-Dimensional Nuclear Magnetic Resonance in Liquids, Delft University Press, 
Dordrecht, 1982. 
35 Palmer III, A. G.; Cavanagh, J.; Wright, P. E.; Rance, M.; J. Magn. Reson., 1991, 151-170. 
36 Bax, A.; Summers, M. F.; J. Am. Chem. Soc., 1986, 2093-94. 
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very dissimilar, making necessary the optimization of the experiment for each 
kind of coupling. Consequently, in many HMBC spectra not all of the 
correlation peaks which could be expected from the structure of the molecule 
are existent. Cross peaks are between protons and carbons that are two or three 
bonds away while direct one-bond cross-peaks are suppressed. In conclusion, 
this experiment allows the connection of the fragments and the assembling of 
the structure of the molecules. 
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CHAPTER 3 
DISCOVERY OF NEW MARINE NATURAL PRODUCTS FROM 
INVERTEBRATES 
 
3.1. Introduction  
For the research of new active metabolites, the natural world offers an endless 
number of amazing matters. However, many of the most intriguing problems 
concern compounds only available in definitely minute quantities. Through the 
bioassay-guided separations, original compounds with different activities can 
be isolated from various invertebrates. In addition, update spectroscopic and 
mass spectrometry techniques provide an improvement of the study of the 
compounds that exsist in nature in infinitesimal amounts. The researcher, in the 
discovery of new bioactive compounds follows different steps such as the 
isolation of major quantities of compound, the defining of its structure and the 
attempt to use it in the pharmaceutical field.  
Since the marine organisms rapresent a reach source of bioactive metabolites, I 
have partly focused my attention on the investigation of the marine 
invertebrates, such as sponges and tunicates.  
Sponges, lacking any digestive, nervous, muscular, circulatory systems or any 
physical defence from their predators, just produce secondary metabolites, 
which are involved in their chemical defence, and are essential for their 
survival. In fact, many species are composed of toxic substances, probably to 
intimidate predators and also to defend their place in the marine ecosystem.  
Several promising compounds have been identified from marine sponges. They 
possess pronounced biological activity and they already reached advanced 
stages of clinical trials, mostly for the treatment of cancer, and some of them 
have been selected as candidates for extended preclinical evaluation. 
Lately, ascidians have increasingly become the target of natural products 
research and as result many new ascidian metabolites have been obtained, 
raising the interest of both pharmacologists and synthetic chemists.  
Ascidians belong to the phylum Chordata, which comprises all vertebrate 
animals, including mammals. Therefore, they represent the most evolved group 
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of animals commonly investigated by marine natural products chemists. These 
species belong to the class of tunicates because the covering of their body 
looks like a tunic.  
While adult ascidians are exclusively marine invertebrates and resemble to the 
other chordates, their larvae look like amphibian tadpoles and contain 
notochorods, pharyngeal slits, dorsal hollow nerve cords, all of which are lost 
during development. There are approximately 2000 living species of tunicates, 
and ascidians are the most abundant among them. As regard the morphology of 
adult ascidians, the ones which live solitary have a length ranged from 1 cm up 
to 15cm while those that live in colonies don’t exceed the length of 5 cm. Some 
of them are of undefined shape, resembling sponges or fleshy coelenterates. 
The contractions causing sea squirt to spray water stream allow inexperienced 
observers to distinguish tunicates from other marine invertebrates.  
 
3.2. Phallusiasterol C, a new disulfated steroid from the Mediterranean 
Tunicate Phallusia fumigata 
 
The chemical diversity shown by marine steroids depend on the basic carbon 
skeleton extensive oxygenation, cleavage and/or re-arrangement on the rings of 
tetracyclic nucleus, and alteration of the side chain.37,38,39,40,41  
In fact, “usual” sterols generally present a 3-hydroxycholestane or 3-hydroxy-
Δ5-cholestane nucleus and a C8–C10 side chain42, whereas marine sterols show 
one or both the distinctive features of carbon side chains in the C10 to C12 
range, involving loss of carbon atoms or their addition at other positions than 
C-24, and multiple oxygenation of the side chain and/or the nucleus.43 The new 
steroidal structures, isolated from sea organisms, are more than 1600. In 
                                                          
37 Lakshmi, V.; Kumar, R. Nat. Prod. Res. 2009, 23, 801–850.  
38 Sarma, N.S.; Krishna, M.S.; Pasha, S.G.; Rao, T.S.P.; Venkateswarlu, Y.; Parameswaran, 
P.S. Chem. Rev. 2009, 109, 2803–2828.  
39 Zhang, W.; Guo, Y.W.; Gu, Y.C. Curr. Med. Chem. 2006, 13, 2041–2090.  
40Sica, D.; Musumeci, D. 2004, 69, 743–756.  
41 Sun, P.; Meng, L.Y.; Tang, H.; Liu, B.S.; Li, L.; Yi, Y.; Zhang, W. J. Nat. Prod. 2012, 75, 
1656–1659.  
42 Goad, L.J.; Scheuer, P.J., Ed.; Academic Press: New York, NY, USA, 1978; Volume 2, pp. 
76–172. 
43 Schmitz, F.J.; Scheuer, P.J., Ed.; Academic Press: New York, NY, USA, 1978; Volume 1, 
pp. 241–297. 
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particular, they have been isolated mainly from marine invertebrates, including 
algae, porifera, and tunicates.42,43 The structural diversity of these metabolites, 
especially the polar sterols, is reflected in a variety of different 
pharmacological properties, including cytotoxic44, antifeedant45, 
spermatostatic46, anti-inflammatory47 and anti-human cytomegalovirus48 
(HCMV) activities. Particularly, the role of marine steroids, as nuclear receptor 
ligands, has been recently highlighted.49 Sulfated steroids endowed with dual 
farnesoid X receptor (FXR) and pregnane X receptor agonism–antagonism 
have been recognized like solomonsterols A (9) and B (10), isolated from the 
sponge Theonella swinhoei,50,51 and phallusiasterol A (7), previously isolated 
from the Mediterranean ascidian Phallusia fumigata, together with its C-6 
epimer phallusiasterol B52 (8, Figure 3.1).  
Specifically, investigation of phallusiasterols effects on the activity of 
pregnane-X-receptor (PXR) has shown that phallusiasterol A induces PXR 
transactivation in HepG2 cells and stimulates the expression of the PXR target 
genes CYP3A4 and MDR1 in the same cell line, whereas phallusiasterol B was 
inactive. This study confirmed the role of steroids in regulating the nuclear 
receptors (NR) activity, and highlighted a crucial reliance on some structural 
features, like the configuration at C-6, of the ligand-receptor binding.  
Particularly, during my research I have been dealing with the re-investigation 
of a new collection of P. fumigata. This study led to the isolation, from the 
                                                          
44 Yan, X.H.; Lin, L.P.; Ding, J.; Guo, Y.W. Bioorg. Med. Chem. Lett. 2007, 17, 2661–2663.  
45 Li, R.; Shao, C.L.; Qi, X.; Li, X.B.; Li, J.; Sun, L.L.; Wang, C.Y. Mar. Drugs. 2012, 10, 
1422–1432.  
46 Tillekeratne, L.M.V.; Liyanage, G.K.; Ratnasooriya, W.D.; Ksebati, M.B.; Schmitz, F.J. J. 
Nat. Prod. 1989, 52, 1143–1145.  
47 Cheng, S.Y.; Huang, Y.C.; Wen, Z.H.; Hsu, C.H.; Wang, S.K.; Dai, C.F.; Duh, C.Y. 
Steroids. 2009, 74, 543–547.  
48 Chen, W.H.; Wang, S.K.; Duh, C.Y. Mar. Drugs. 2011, 9, 1829–1839. 
49 Blumberg, B.; Sabbagh, W., Jr.; Juguilon, H.; Bolado, J., Jr.; van Meter, C.M.; Ong, E.S.; 
Evans, R.M. Genes Dev. 1998, 12, 3195–3205.  
 
50 Festa, C.; de Marino, S.; D’Auria, M.V.; Bifulco, G.; Renga, B.; Fiorucci, S.; Petek, S.; 
Zampella. J. Med. Chem. 2011, 54, 401–405.  
51 Mencarelli, A.; D’Amore, C.; Renga, B.; Cipriani, S.; Carino, A.; Sepe, V.; Perissutti, E.; 
D’Auria, M.V.; Zampella, A.; Distrutti, E.; Fiorucci, S.  Mar. Drugs. 2013, 12, 36–53.  
52 Imperatore, C.; D’Aniello, F.; Aiello, A.; Menna, M.; Fiorucci, S.; D’Amore, C.; Sepe, V. 
Mar. Drugs. 2014, 12, 2066–2078.  
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more polar fraction of the butanol extract, of a new disulfated sterol, which has 
been named phallusiasterol C (6, Figure 3.1), whose structure was elucidated 
by spectroscopic means. Several subsequent normal-phase chromatographies of 
the ethyl acetate extract of the ascidian P. fumigata, collected from the bay of 
Pozzuoli (Napoli, Italy), provided the isolation of the compound 6 in its pure 
form.  
A pseudomolecular ion at m/z 567.2054 [M–Na+] ¯ was seen in the high-
resolution ESI mass spectrum (negative ion mode), suggesting for compound 6 
a molecular formula of C26H40NaO8S2
- (calcd. 567.2057), which indicated six 
unsaturation degrees. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Structures of phallusiasterol C (6), phallusiasterols A (7) and B (8), 
solomonsterols A (9) and B (10), and chalinulasterol (11). 
 
The ESI and MS/fragmentation pattern of 6 revealed the presence of two 
sulfate groups from the peaks 545 (M in hydrogen form), 272 (double charged 
species), and 447 [M NaHSO4 Na
+]. The 1H NMR spectrum (CD3OD) of 6 
suggested its steroidal structure, with two up-field methyl singlets at δ 0.72 
(H3-18) and 1.03 (H3-19) and one methyl doublet at δ 1.03 (J=6.4 Hz, H3-21). 
Other proton resonances, combined with 13C NMR and mass data, highlighted 
the presence of one secondary (δH 4.14, dddd, J=11.4, 11.4, 4.8, 4.8 Hz, δC 
80.0, CH) and one primary (δH 3.88, dd, J=9.3, 6.0 Hz; δH 3.74, dd, J=9.3, 7.8 
Hz, δC 73.8, CH2) sulfoxy groups in the molecule. Furthermore, three olefin 
signals, resonating in the proton spectrum at δ 5.38 (dd, J=6.9, 3.3 Hz, 1H, H-
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6), 5.35 (dd, J=15.3, 8.5 Hz, 1H, H-22), and 5.28 (dd, J=15.3, 7.0 Hz, 1H, H-
23), were assigned to two double bonds, one trisubstituted and one 
disubstituted, based on the four down-field resonances present in the 13C NMR 
spectrum at δC 141.5 (C), 123.4 (CH), 138.5 (CH) and 130.2 (CH).  
The interpretation of COSY, HSQC and HMBC 2D NMR experiments 
permitted the assembly of the steroidal backbone and the assignment of all the 
protons and carbons of the tetracyclic system to the relevant resonances. 
(Table 3.1). The location of the secondary sulfoxy group at C-3 and the Δ5(6) 
position of the endocyclic double bond were so deduced. The HMBC 
correlation peaks of the methyl protons H3-19 with C-1, C-5, C-9, and C-10 
and of H3-18 with C-12, C-13, C-14, and C-17 located the A/B and C/D ring 
junctions and completed the planar structure determination of the steroid ring 
system. The nature of the side chain was readily deduced by COSY map 
analysis. A single 1H-1H spin system was delineated, starting at the methyl 
doublet at δ 1.03 (H3-21) which was correlated to the proton at δ 2.06 (H-20). 
The latter was coupled with both the H-17 methine proton (δ 1.67) and the 
olefinic proton at δ 5.35 (H-22), then, in turn coupled with the other olefin 
proton at δ 5.28 (H-23). This showed the Δ22 position of the remaining double 
bond, whose E-configuration was suggested by the J value (15.3 Hz) of H-22 
and H-23. The coupling of H-23 to the multiplet at δ 2.44 (H-24), which was in 
turn coupled both to the methyl protons at δ 1.02 (H3-26) and the sulfoxy 
methylene protons at δ 3.74 (H-25a) and δ 3.88 (H-25b), completed the 
assignment, indicating a 24-methyl-25-sulfoxy C26 side chain for 6 (Figure 
3.2). The relative stereochemistry of phallusiasterol C (6) with the B/C and 
C/D trans ring junctions, was established through the analysis of ROESY data 
and coupling constant analysis. The axial orientation of H-8, H-9 and H-14 was 
apparent from their respective coupling constants, as well as the orientation of 
the angular methyl groups from the ROESY correlations of both H3-18 and H3-
19 with H-8 and the axial H-11β.  
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Figure 3.2. COSY segments (represented as colored bonds) and key ROESY 
correlations (arrows) for the phallusiasterol C (6). 
 
 
Table 3.1. 1H (700 MHz) and 13C (125 MHz) NMR data for phallusiasterol C (6) in 
CD3OD. 
a Assignments may be interchanged. b Overlapped by other signals. 
 
On this skeleton, the 3β-sulfoxy configuration was assigned on the basis of the 
coupling pattern of H-3 indicating its axial orientation.53,54,55 Thanks to this 
                                                          
53 Aiello, A.; Fattorusso, E.; Menna, M.; Carnuccio, R.; Iuvone, T. Steroids 1995, 60, 660–673.  
54 Fujimoto, Y.; Yamada, T.; Ikekawa, N. Chem. Pharm. Bull. (Tokyo) 1985, 33, 3129–3133.  
55 Notaro, G.; Piccialli, V.; Sica, D.; Corriero, G. J. Nat. Prod. 1991, 54, 1570–1575.  
Position δH (mult., J in Hz) δC HMBC Pos. δH (mult., J in Hz) δC HMBC 
1β 1.90, dt, (13.5, 3.6) 
38.4 
2, 5, 10, 19 - - - - 
1α 1.10, m 2, 3, 10, 19 13 - 43.4 - 
2β 1.63, m a 
29.9 
1, 3, 10 14α 1.02 b 58.2 
8, 13, 15, 16, 
18 
2α 2.07, m a 1, 3, 10 15β 1.07, m a 
25.3 
13, 14, 16, 17 
3α 
4.14, dddd, (11.4, 
11.4, 4.8, 4.8) 
80.0 1, 2, 4 15α 1.58 a,b 8, 14, 16 
4β 2.34, dd, (13.2, 11.4) 
40.3 
2, 3, 5, 6, 10 16β 1.28, m a 
29.7 
13, 15, 17 
4α 
2.53, ddd, (13.2, 4.8, 
2.2) 
2, 3, 5 16α 1.71, m a 13, 17, 20 
5 - 141.5 - 17 1.17, m 57.2 
13, 15, 16, 20, 
22 
6 5.38, dd, (6.9, 3.3) 123.4 4, 7, 8, 10 18 0.72, s 12.5 12, 13, 14, 17 
7β 
1.98, dt, (13.4, 6.9, 
3.3) 33.0 
5, 6, 8, 9 19 1.03, s 19.7 1, 5, 9, 10 
7α 1.55 b 5, 8, 14 20 2.06, m 41.5 17, 21, 22, 23 
8β 1.48, m (qd, 10.7, 4.3) 33.2 7, 9, 14 21 1.03, d, (6.4) 19.7 17, 20, 22 
9α 
 
0.96, ddd (13.2, 10.7, 
4.3) 
51.7 8, 10, 11, 19 22 5.35, dd, (15.3, 8.5) 138.5 20, 21, 23, 24 
10 - 37.7 - 23 5.28, dd, (15.3, 7.0) 130.2 
20, 21,22, 25, 
26 
11β 1.55 b 
22.1 
9, 10, 12 24 2.44, m 37.6 22, 23, 25,26 
11α 1.51, m 9, 10, 12 25a 3.88, dd, (9.3, 6.0) 
73.8 
23, 24, 26 
12β 2.01, dt, (12.9, 3.5) 
41.0 
11, 14 25b 3.74, dd, (9.3, 7.8) 23, 24, 26 
12α 1.18, m 9, 13, 14 26 1.02, d, (6.2) 21.2 23, 24, 25 
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information, the structure of phallusiasterol C (6) was established as (22E)-
26,27-dinor-24ξ-methyl-cholesta-5,22-dyen-3β, 25-diyl-3,25-sodium disulfate. 
Based on the reported activity of phallusiasterols A and B, as nuclear receptor 
ligands, the effects of phallusiasterols C as modulators of PXR receptor have 
been also investigated. A transactivation assay on HepG2 cells, a human 
hepatocarcinoma cell line, has been performed. These studies displayed that, 
despite the structural similarity with solomonsterol A for the short and sulfated 
side chain, compound 6 was inactive as PXR agonist. Additionally, it also 
failed to reverse the induction of luciferase activity caused by rifaximin, 
indicating that it was not a PXR antagonist (Figure 3.3). Similar results have 
been obtained by analyzing the effect exerted by 6 in terms of regulation of 
PXR mediated induction of two PXR target genes, CYP3A4 and MDR1, in the 
same cell line. In this assay, compound 6 failed to induce the expression of 
both target genes (data not shown).     
 
 
 
 
          
  
 
 
 
 
 
 
 
 
(a) (b) 
  
 
Figure 3.3. (a, b) Luciferase reporter assay. HepG2 cells were transiently transfected 
with pSG5-PXR, pSG5-RXR, pCMV-βgalactosidase and p(CYP3A4)-TK-Luc vectors 
and then stimulated with (a) 10 μM rifaximin or phallusiasterol C (6) for 18 h, or (b) 
10 μM rifaximin alone or in combination with 50 μM of compound 6. Relative 
Luciferase Units were normalized with β-galactosidase Units (RLU/βgal). All 
experiments were performed in triplicate.  
NT, not treated cells. R, Rifaximin. *P < 0.05 versus NT cells. Data are mean ± SE. 
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These results, although negative, were important for the knowledge of the 
structure-PXR regulating activity relationship, concerning the sulfated steroids. 
In the binding model, proposed for solomonsterols to the PXR receptor, a clear 
stabilizing interaction between the side chain sulfate group and the positively 
charged Lys210 is observed.49 This model was supported by many studies on 
chalinulasterol (11), which has a structural relationship with solomonsterols 
and differ from the latter in having a chlorine atom instead of a sulfate function 
at position C-24 of the side chain.56 Chalinulasterol lacked any PXR 
modulating activity and, as a consequence, an essential role of the sulfate group 
present in the side chain has been proposed. However, the activity of 
phallusiasterol A (7) as PXR agonist, which can be compared to that of 
rifaximin, a well characterized ligand for the human PXR, opposes this 
assumption since it presents a "regular" sterol side chain (Figure 3.1). Instead, 
the feature and/or the shape of the region around the A/B ring junction seems 
to be crucial; in fact, both phallusiasterol B (8), which differs from 
phallusiasterol A only for the configuration at C-6, and phallusiasterol C, 
showing the Δ5(6) double bond, lacked any PXR modulating activity (Figure 
3.1). In conclusion, the investigation of the possible role of phallusiasterol C as 
modulator of the PXR nuclear receptor revealed important structural 
requirements for the PXR nuclear receptor activity of sulfated steroidal 
structures. 
 
3.3. Cytotoxic thiazinoquinones from the Mediterranean ascidian Aplidium 
conicum. 
Ascidians of the genus Aplidium57 are recognized as an important source of 
chemical diversity and bioactive natural products. Among the compounds 
isolated by this genus are present many meroterpenes. These compounds form 
a class of complex metabolites, which derive from a mixed terpenoid-
                                                          
56 Teta, R.; Della Sala, G.; Renga, B.; Mangoni, A.; Fiorucci, S.; Costantino, V. Mar. Drugs. 
2012, 10, 1383–1390.  
57 Fenical, W. in Food-Drugs from the Sea Proceedings. (Eds.: H. H. Webber, G. D. Ruggieri), 
Marine Technology Society, Washington DC, 1976, 4, 388-394. 
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polyketide biosynthetic pathway and display a structural diversity.58 The 
quantity of meroterpenes in the species Aplidium conicum depends on the place 
where they are collected. For example, it has been found out that the specimens 
of A. conicum situated in Tarifa Island, in Spain, contained geranyl 
hydroquinone and its hydroxylated and/or cyclized analogues as well as 
various chromenols.59  
From samples of the same ascidian, collected in Italy along Sardinia coasts, my 
research group have isolated a large group of new meroterpenes, with different 
polycyclic skeletons, but all show an unusual thiazinoquinone ring.  
In the present thesis, the electrochemistry of four natural thiazinoquinones (12-
15; Figure 3.4) from Aplidium species was reported in order to clarify the 
mechanism of action which is the basis of their cytotoxicity. The chemical and 
farmacological characterization of these compounds was previously 
discussed.60,61,62 This work was already performed and completed for the 
compounds 12-15 that showed an interesting cytotoxic activity on different cell 
lines60,61,62 (Table 3.2). 
The electrochemical studies were elaborated together with the research group 
of Prof. Doménech-Carbò (University of Valencia, Spain) which, using an 
innovative technique, “the solid-state electrochemistry following the 
voltammetry of microparticles technique (VMP)”, has provided information 
about the electrochemical response of the compounds, either alone or in 
presence of heme and O2 in order to test the ability of the compounds to react 
with heme and the reactive oxygen species (ROS). It is known that because of 
their electrophilic properties some natural quinones can react directly with 
cellular nucleophiles, including soluble and protein thiol groups, and may 
                                                          
58 Zubìa, E.; Ortega, M. J.; Salvà, J. Mini-Rev. Org. Chem. 2005, 2, 389-399. 
59 Garrido, L.; Zubía, E.; Ortega, M. J.; Salvá, J. J. Nat. Prod. 2002, 65, 1328-1331. 
60 Aiello, A.; Fattorusso, E.; Luciano, P.; Menna, M.; Esposito, G.; Iuvone, T.; Pala, D. Eur. J. 
Org. Chem. 2003, 898-900. 
61 Aiello, A.; Fattorusso, E.; Luciano, P.; Mangoni, A.; Menna, M. Eur. J. Org. Chem. 2005, 
5024-5030. 
62 Aiello, A.; Fattorusso, E.; Luciano, P.; Macho, A.; Menna, M.; Muñoz, E. J. Med. Chem. 
2005, 48, 3410-3416. 
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inhibit critical processes in the cell.63,64 Some quinones intercalate between the 
base pairs of DNA leading to blockage of DNA, RNA, and protein synthesis65 
while some others stabilize binding of nuclear topoisomerase II to DNA 
resulting in protein-associated DNA strand breaks.66,67 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Structures of the studied compounds 
 
In addition, cytotoxic quinones can exert their effects through the formation of 
redox-reactive species.68,69,70 Single-electron reduction of quinones is catalyzed 
by flavoenzymes, resulting in the formation of semiquinone free radicals. 
These latter can then either bind directly to DNA, protein, and lipid, or undergo 
further redox reactions.71,72,73,74 In recent years, particular interest has been paid 
                                                          
63 Di Monte, D.; Ross, D.; Bellomo, G.; Eklow, L.; Orrenius, S. Arch. Biochem. Biophys. 1984, 
235, 334-342. 
64 Ross, D.; Thor, H.; Orrenius, S.; Moldeus, P. Chem.-Biol. Interact. 1985, 55, 177-184. 
65 Pigram, W.J.; Fuller, W. L.; Hamilton, D. Nature 1972, 235, 17-19. 
66 Tewey, K.M.; Rowe, T.C.; Yang, L.; Halligan, B.D.; Liu, L.F. Science 1984, 226, 466-468. 
67 Pommier, Y.; Schwartz, R.E.; Zwelling, L.A.; Kohn, K.W. Biochemistry 1985, 24, 6406-
6410. 
68 Cohen, G.M.; Doherty, M. d’A.; Br. J. Cancer Suppl. 1987, 8, 46-52. 
69 Samoilova, R. I.; Crofts, A. R.; Dikanov, S. A. J. Phys. Chem. 2011, 115, 11589–11593. 
70 Verrax, J.; Beck, R.; Dejeans, N.; Glorieux, C.; Sid, R.C. Pedrosa, B.; Benites, J.; Vásquez, 
D.; Valderrama, J.A.; Calderon, P.B. Anticancer Agents Med Chem. 2011, 11, 213-221. 
71 Sinha, B.; Gregory, J.L. Biochem. Pharmacol. 1981, 30, 2626-2629. 
72 Goormaghtigh, E.; Pollakis, G.; Ruysschaert, J.M. Biochem. Pharmacol. 1983, 32, 889-893. 
73 Bachur, N.R.; Gordon, S.L.; Gee, M.V.; Kohn, H. Proc. Natl. Acad. Sci. USA 1979, 76, 954-
957. 
74 Muller, F.; Crofts, A. R.; Kramer, D. M. Biochemistry. 2002, 41, 7866–7874. 
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to quinone-based compounds forming reactive semiquinone radicals which can 
then reduce oxygen to form reactive oxygen species (ROS), such as superoxide 
radicals (O2·), and regenerate the parent molecule.
68 This pathway has been 
considered as operative for some natural quinones75,76,77 but it is not the sole 
leading to ROS generation. Semiquinone free radical species can indeed 
interfere with the whole electron transport chain in the mitochondria, being 
either oxidized or reduced.74 In this scenario, thiaplidiaquinone B (12, Figure 
3.4), a cytotoxic prenylated benzoquinone isolated from the marine ascidian 
Aplidium conicum, was proved78 to induce apoptosis in Jurkat cells due to a 
rapid overproduction of intracellular ROS, which mediate the collapse of the 
mitochondrial transmembrane potential. Kinetic experiments showed that ROS 
production preceded the disruption of the mitochondrial potential, and the later 
one paralleled the appearance of apoptotic cells.78  
 
Table 3.2. Source and cytotoxic activity against cancer cell lines of the studied 
compounds. 
a Human breast adenocarcinoma cells 
b Rat glioma cells 
c Rat basophilic leukaemia cells 
d Human leukemia T Jurkat 
e NT: not tested 
 
                                                          
75 Inbaraj, J. J.; Gandhisan, R.; Murugesan, R. Free Radic. Biol. Med. 1999, 26, 1072-1078. 
76 Benchekroun, M. N.; Myers, C. E.; Sinha, B. K. Free Radic. Biol. Med. 1994, 17, 191-200. 
77 Huang, P.; Feng, L.; Oldham, E. A.; Keating, M. J.; Plunkett, W. Nature (London) 2000, 
407, 390-395. 
78 Aiello, A.; Fattorusso, E.; Luciano, P.; Macho, A.; Menna, M.; Muñoz, E. J. Med. Chem. 
2005, 48, 3410–3416. 
Cmp Source IC50 (µM) 
 
 
MCF-7a C6b 
RBL-
2H3c 
Jurkatd 
12 
A. conicum 
Capo Caccia (Italy) 
NTe NT NT 3  
13 A. conicum NT 20.3 231.6 NT 
14 
A. conicum, 
Tarifa Island (Spain) 
44.5 NT NT NT 
15 
A. conicum, 
Tarifa Island (Spain) 
125.0 NT NT NT 
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In the present work, VMP was applied to the study of the electrochemistry of 
thiaplidiaquinone B78 (12) as well as other cytotoxic marine-derived 
meroterpenes, such as conicaquinone A (13), conithiaquinones A and B (14, 
15), also isolated from A. conicum (Figure 3.4).79,80 The methodology 
previously used to study several synthetic quinone analogues81 was expanded 
by combining conventional solution phase and VMP approaches incorporating 
electrochemically generated ROS82,83,84 and by integrating computational 
studies performed on the starting quinone structures, as well as, on the reduced 
species. Interaction with dsDNA was also monitored in order to obtain further 
information to be correlated with the observed effects of these natural 
thiazinoquinones on cells growth and viability.   
3.3.1. Electrochemical studies 
The voltammetric response of the studied compounds in DMSO solution was a 
consequence of a mainly reversible one-electron redox couple, corresponding 
to the quinone to semiquinone reduction, thus coinciding to the typical 
electrochemistry of quinones in nonaqueous electrolytes.85 In light of the low 
solubility in water of these compounds, solid state electrochemistry was 
performed on microparticulate films of them dipped into aqueous PBS at 
physiological pH. Figure 3.5 displays the negative- and positive-going scan 
cyclic voltammograms of 12. Reduction peaks occur, in the initial cathodic 
scan (Figure 3.5 a), at 0.65(C1) and 1.03 V vs. Ag/AgCl (C2).  
 
                                                          
79 Aiello, A.; Fattorusso, E.; Luciano, Menna, M.; Esposito, G.; Iuvone, T.; Pala, D. Eur. J. 
Org. Chem. 2003, 898-900.  
80 Menna, M.; Aiello, A.; D’Aniello, F.; Imperatore, C.; Luciano, P.; Vitalone, R.; Irace, C.; 
Santamaria, R. Eur. J. Org. Chem. 2013, 3241-3246. 
81Imperatore, C.; Persico, M.; Aiello, A.; Luciano, P.; Guiso, M.; Sanasi, M.F.; Taramelli, D.; 
Parapini, S.; Cebrián-Torrejón, G.; Doménech-Carbó, A.; Fattorusso, C.; Menna, M. RSC Adv. 
2015, 7, 70689-70702.  
82 Yano, T.; Tryk, D.A.; Hashimoto, K.; Fujishima, A. J. Electrochem. Soc. 1998, 145, 1870-
1876. 
83 Marselli, B.; Garcia-Gomez, J.; Michaud, P.-A.; Rodrigo, M.A.; Comninellis, C. J. 
Electrochem. Soc. 2003, 150, D79–D83. 
84 Kapałka, A.; Foti, G.; Comninellis, C. Electrochim. Acta. 2009, 54, 2018–2023. 
85 Zuman, P.; Perrin, C.L. Organic Polarography, John Wiley & Sons, New York, 1969. 
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Figure 3.5. Cyclic voltammograms of 12 microparticulate films on glassy carbon 
electrode immersed into 0.10 M PBS at pH 7.4. Potential scan initiated at 0.0 V a) in 
the negative and b) in the positive directions; potential scan rate 50 mV s1. 
 
These signals are coupled, in the consequent anodic scan, with a feeble 
shoulder at 0.80 (A2) and a well-defined, although feeble, oxidation peak at 
0.45 V (A1) which goes before a wide oxidation signal at 0.04 V (A3).This 
peak is not found in initial anodic scan voltammograms (Figure 3.5 b), thus 
proving that the process A3 is due to the oxidation of any product generated in 
previous cathodic steps. 
The voltammetry of all the studied quinones was analogous, but the potential 
separation and the relative height of peaks C1 and C2 differed considerably. 
This is shown in Figure 3.6, where semi-derivative deconvolution of the 
voltammetric curves was carried out in order to improve peak resolution. As 
can be seen in this figure, 13 and 14 exhibit peaks C1 and C2 of similar 
intensity and the peak A1 remains well-defined. On the other hand, the peak C1 
is relatively weak in 12 and 15 and the former displays some weak signals A1 
and A3, while the latter presents a relatively intense peak A1 without showing 
peak A3. 
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Figure 3.6. Cyclic voltammograms, after semi-derivative convolution, of a) 13; b) 14; 
c) 15; d) 12. microparticulate films on glassy carbon electrode immersed into 0.10 M 
PBS at pH 7.4. Potential scan initiated at 0.0 V a) in the negative and b) in the positive 
directions; potential scan rate 50 mV s1. 
 
This voltammetry can be explaned on the basis of the precise knowledge of the 
electrochemistry of quinones in solution phase86 and the Lovric and Scholz 
model on the electrochemistry of ion-insertion solids.87,88,89,90,91 Considering 
the organic compounds in contact with aqueous electrolytes, solid state 
electrochemical reaction initially occurs at the solid particle/base 
electrode/electrolyte three-phase junction and spreads through the solid via 
proton insertion coupled with electron hopping between immobile redox 
centers in the solid.87-91 
The reduction of quinones (Q) in aqueous solution takes place typically via two 
rounds of electron-transfer (E) coupled with proton acceptance (chemical 
reaction (C)) obtaining a quinone radical anion or semiquinone (Q●─) which is 
                                                          
86 Chambers, J.Q. Electrochemistry of quinones. Wiley, New York, 1988. 
87 Lovric, M.; Scholz, F. J. Solid State Electrochem. 1997, 1, 108-113. 
88 Lovric, M., Hermes, M.; Scholz, F. J. Solid State Electrochem. 1998, 2, 401-404. 
89 Oldham, K.B. J. Solid State Electrochem. 1998, 2, 367-377. 
90 Lovric, M.; Scholz, F. J. Solid State Electrochem. 1999, 3, 172-175. 
91 Schröder, U.; Oldham, K.B.; Myland, J.C.; Mahon, P.J.; Scholz, F. J. Solid State 
Electrochem. 2000, 4, 314-324. 
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protonated producing a radical (HQ●) that is subsequently reduced to QH─, and 
new protonation reaction generates the corresponding hydroquinone (QH2) 
species (Scheme 3.1).  
 
 
Scheme 3.1.. Reduction pathway of quinone to hydroquinone in aqueous environment.  
 
The general reduction process can be described in terms of an ECEC 
mechanism which appears, depending on the pH and the buffering capacity of 
the electrolyte, as a unique voltammetric couple (C1/A1), where the cathodic 
wave often (Figure 3.6 a, b) looks like two superimposed signals.85-86 
The comparison with the electrochemistry of synthetic thiazinoquinones81 
suggests that the above electrochemical process would be followed by the 
reduction of the SO2 unit to SO at more negative potentials (C2/A2 couple). The 
peak A3, which is depleted when the peak A2 is well developed (Figure 3.6 b), 
can be due to the oxidation of the reduced form resulting from the initial 
reduction C1 through the NH motif. In some cases, (Figure 3.6 b, d), a not well 
defined anodic shoulder ca. +0.6 V (A4) appears. This process can be attributed 
to the oxidation of the NH unit of the parent quinone.81 
 
3.3.2. Interaction with ROS 
In order to test the possible interaction of the studied compounds with ROS, the 
voltammetry of microparticulate films of the same samples in contact with air-
saturated PBS was carried out. Figure 3.7 compares the cathodic response of 
an unmodified glassy carbon electrode in contact with air-saturated PBS at 
physiological pH, with those of microparticulate films of the studied natural 
products on that electrode.  
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Figure 3.7. Cyclic voltammograms, after semi-derivative deconvolution, of a) 
unmodified glassy carbon electrode in contact with air-saturated PBS at pH 7.4 and b-
d) electrode modified with b) 13; c) 14; d) 12. Potential scan rate 50 mV s1.  
 
 
At the unmodified glassy carbon electrode, dissolved oxygen yields a reduction 
wave at ca. 0.85 V (Cox) which can be assigned, following literature, to the 
one-electron reduction of O2 to the radical anion superoxide O2· which is 
rapidly protonated and reduced to H2O2 (Equations 3.1-3.6).
91,92,93,94  
Indeed, the electrochemical reduction at carbon electrodes of oxygen dissolved 
in aqueous electrolytes (Cox) proceeds through a multistep pathway 
complicated by adsorption processes initiated by the one-electron reduction of 
O2 to superoxide radical anion.  
   O2 + e

    O2· (ads)    (3.1)  
                                                          
92 Nagaoka, T.; Sakai, T.; Ogura, K.; Yoshino, T. Anal. Chem. 1986, 58, 1953-1955. 
93 Xu, J.; Huang, W.; McCreery, R.L. J. Electroanal. Chem. 1996, 410, 235-242. 
94 Ratsgar, S.; Deng, H.; Cortés-Salazar, F.; Scanlon, M.D.; Pribil, M.; Amstutz, V.; Karyakin, 
A.A.; Shahrokhian, S.; Girault, H.H. ChemElectroChem. 2014, 1, 59-63. 
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The generated radical anion undergoes protonation (3.2) followed by 
electrochemical reduction (3.3): 
 
O2· (ads) + H2O    HO2· (ads) + OH    (3.2) 
:  
HO2· (ads) + e    HO2    (3.3)  
Alternatively, it undergoes disproportionation: 
 2O2· (ads) + H2O    HO2 + O2 + OH-   (3.4)  
Leading to the final generation of H2O2: 
HO2

+ H2O    2HO·+ OH  (3.5) 
HO· + HO·  H2O2     (3.6) 
 
Through this series of processes, reactive radicals HO2
• and HO• can be formed 
at the electrode surface, in agreement with literature on electrochemical 
generation82-84 and redox potentials95,96,59-60 of ROS. Accordingly, the process 
Cox in Figure 3.7a corresponds to a multistep electrochemical reduction of 
dissolved O2 resulting in the generation of ROS, the signals Aox and Ahox being 
attributable to the oxidation of O2
• and HO2
•, respectively.97 
The Cox peak shows a weak anodic counterpart (Aox) and is accompanied by an 
oxidation peak at +0.75 V (Ahox). At films of the natural thiazinoquinones 
(Figure 3.7 b-d), the signals Cox and Aox are depleted and preceded by the first 
reduction process of the compound (C1), corresponding, in PBS, to the 
formation of HQ·. The depletion of the signal is relatively large for 13 and 14 
and much less intense for 12 and 15. Interestingly, in the anodic scan, the 
oxidation peak at ca. +0.75 V (Ahox), appearing in the voltammograms at the 
                                                          
95 Jinnouchi, R.; Anderson, A.B. J. Phys. Chem. 2008, 112, 8747-8750. 
96 Anderson, A.B.; Jinnouchi, R.; Uddin, J. J. Phys. Chem. 2013, 117, 41-48. 
97 Cofré, P.; Sawyer, D.T. Anal. Chem. 1986, 58, 1057-1062. 
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unmodified glassy carbon electrode (Figure 3.7 a), is also considerably 
weakened (Figure 3.7 b-d).  
The voltammetric features in Figure 3.7 can be rationalized on assuming that 
there is another pathway operating in the oxidation of dissolved 
peroxide/hydroperoxide at quinone films, which competes with its 
electrochemical oxidation. This can be tested by means of voltammetric features 
for the oxidation of the hydroperoxide radical (signal Ahox), as illustrated in 
Figure 3.8, where the square wave voltammograms of air-saturated PBS in 
contact with unmodified and 14-modified glassy carbon electrode at two different 
square wave frequencies, are shown. At a relatively high frequency (Figure 3.8 
a); and at a short experimentation time, both the unmodified and 14-modified 
electrode display an essentially identical signal Ahox, thus denoting that the 
generation of hydroperoxide radical occurs. When the frequency is lowered 
(Figure 3.8 b), and the time is longer, the peak Ahox appears at the unmodified 
electrode whereas it vanishes at the 14-modified electrode. This effect was 
observed with essentially identical extent for the thiazinoquinones in this study.  
A rationalization of the above electrochemical features can be proposed taking 
into account that it has been demonstrated that several quinones modify the 
activity of superoxide dismutases (SOD) by undergoing equilibrium reactions 
with superoxide radicals.98 
For quinones with no or short hydrophobic tails, the radical product is a 
semiquinone at much lower yield, likely indicating reduction of quinone by 
superoxide and subsequent loss of most of the semiquinone product by 
disproportionation.69 In solution phase, the depletion of the peak Ahox at ‘long’ 
times (Figure 3.8 b) could be attributed to semiquinone disproportionation but, 
at microparticulate deposits of quinone it appears the most reasonable option to 
attribute the observed voltammetric features to the result of a relatively slow 
reaction of HQ·with the electrochemically generated hydroperoxide. 
 
                                                          
98 Butler, J.; Hoey, B.M. J. Free Radicals Biol. Med. 1986, 2, 77-81. 
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Figure 3.8. Square wave voltammograms at unmodified (red lines) and 14-modified 
(black lines) glassy carbon electrode in contact with air-saturated PBS at pH 7.4. 
Potential scan initiated at -1.05 V in the positive direction; potential step increment 4 
mV; square wave amplitude 25 mV; frequencies of a) 5 and b) 50 Hz. Only the region 
of potentials around the peak Aox is depicted. 
 
 
Experiments in DMSO solution, also representative of the interaction of the 
studied products with oxygen and ROS, were used to complement the above 
scenario.  
Figure 3.9 compares the voltammograms of dissolved oxygen in 0.10 M 
Bu4NPF6/DMSO solutions (Figure 3.9a), 12 in the same electrolyte previously 
deoxygenated (Figure 3.9b) and air-saturated solutions of 14 (Figure 3.9c) and 
15 (Figure 3.9d). As it is well-known, the electrochemical reduction of 
dissolved oxygen in aprotic solvents occurs reversibly at potentials ca. 0.9 V 
(Figure 3.9 a, CO/AO couple) yielding superoxide radical anion. In the absence 
of oxygen, the studied quinones produce an essentially reversible one-electron 
reduction (CQ1/AQ1) to the corresponding semiquinone at ca. 0.75 V followed 
by a second one-electron reduction at ca. 1.5 V (CQ2/AQ2). Voltammograms 
of air-saturated DMSO solutions of such compounds consist of superimposed 
signals for O2 and Q reduction but remarkably, in the anodic scan the anodic 
signal AQ1 is entirely or almost entirely depleted after passing the peak AO 
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which remains essentially unaltered, while the couple CQ2/AQ2 is also 
decreased. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Cyclic voltammograms at glassy carbon electrode, after semi-derivative 
convolution, of different 0.10 M Bu4NPF6/DMSO solutions. a) air-saturated 
electrolyte solution; b) 0.5 mM 12 in deoxygenated electrolyte; c) air-saturated 0.5 
mM 14; d) air-saturated 15. Potential scan rate mV s1. 
 
The depletion of the peak AQ1 and the CQ2/AQ2 couple in the voltammograms 
of air-saturated thiazinoquinone solutions can be considered as indicative of the 
occurrence of a relatively fast reaction between dissolved oxygen and the 
semiquinone radical anion electrochemically generated. The large separation 
between the two one-electron reduction processes of the thiazinoquinones 
(Figure 3.9 b), in sharp contrast with the signal merging recorded in aqueous 
media (Figure 3.5), denotes that there is no significant disproportionation of 
the intermediate semiquinone radical anion and there is no interaction of Q•- 
with the superoxide anion.  
Thus, while the voltammetry of microparticulate films of the studied quinones 
in contact with air-saturated PBS revealed the reduction of the protonated 
semiquinone radicals by the superoxide radical anion, in air-saturated DMSO 
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solution, on the contrary, the semiquinone radical anions are oxidized by 
oxygen. 
This difference can be assessed by performing additional experiments in water-
containing DMSO solution. This can be seen in Figure 3.10 for 12 (in Figure 
3.10 compound 13 is reported). In anhydrous DMSO in the absence (Figure 
3.10a) of dissolved O2, the voltammetric response is identical to all other 
thazinoquinones in this study, with well separated couples CQ1/AQ1 and 
CQ2/AQ2. In air saturated DMSO containing a small concentration of water 
(Figure 3.10 b), an additional couple (CQH/AQH) is recorded, corresponding to 
the overall reduction to hydroquinone, appearing as a unique voltammetric 
couple in presence of water, that is, when the protonated semiquinone species 
can be formed (Figure 3.6). This new couple is placed at ca. 250 mV more 
negative potential than the CQ1/AQ1 couple corresponding to the reversible 
formation of Q•-. This new couple can be attributed to the reversible one-
electron reduction of the protonated semiquinone resulting from the fast 
protonation of the semiquinone radical anion produced in the cathodic step 
CQ1. Consistently with this interpretation, even in a medium such as DMSO 
having high radical scavenging ability69 a weak anodic signal (Ahox) 
attributable to the formation of some radical hydroperoxide as a result of the 
presence of residual water, was recorded at the unmodified electrode (Figure 
3.10c). Again, this signal vanishes more or less intensively in the presence of 
thiazinoquinones, now in the solution phase (Figure 3.10b).  
In summary, the results of these voltammetric studies suggest that all the 
considered natural thiazinoquinones are able to form the semiquinone radical 
species and that this latter, depending on its protonation state, can be reduced 
or oxidized in presence of redox-active compounds, such as, in the case of 
these experiments, O2 and ROS.  
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Figure 3.10. Cyclic voltammograms at glassy carbon electrode, after semi-derivative 
convolution, of different 0.10 M Bu4NPF6/DMSO solutions. a) 0.5 mM 13 b) air-
saturated 0.5 mM 13 + 0.5 mM water; c) air saturated 0.10 M Bu4NPF6/DMSO + 0.5 
mM water. Potential scan rate mV s1. 
 
3.3.3. Interaction with dsDNA 
The interaction between the thiazinoquinones and salmon testes dsDNA was 
studied in DMSO solution. Figure 3.11 compares the cyclic voltammograms of 
a) 13; b) 14; c) 15; d) 12 plus dsDNA solutions. Under these experimental 
conditions, dsDNA remained electrochemically silent. However, the 
voltammetry of the thiazinoquinones experienced significant modifications 
relative to the previously observed response (Figure 3.10). Thus, the CQ1/AQ1 
couple showed peak splitting and weakening of the anodic signal. The new 
cathodic signal (CQA), whose anodic counterpart (AQA) is almost entirely 
absent, can be attributed to the quinone-localized reduction of the dsDNA-
thiazinoquinone complex, a feature parallel to that observed for canthin-6-one 
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alkaloid-modified electrodes,99 which can be considered as indicative of the 
existence of a strong interaction between the thiazinoquinones and dsDNA. 
The weakness of the anodic signal AQA would be the result of secondary post-
electron transfer reactions. 
The voltammograms, however, display a weak couple at less negative 
potentials (CQB/AQB) whose intensity appears to be larger for the compounds 
displaying the lower CQA/AQA signals. The new couple can be attributed to the 
reduction of a thiazinoquinone-dsDNA complex different from that responsible 
of the CQA/AQA couple, so that the overall voltammetric pattern can be 
described in terms of a square scheme such as depicted in Figure 3.12. 
Assuming reversibility, the aforementioned electron transfer processes would 
be coupled with the complexation equilibria between the oxidized (quinone) 
and reduced (semiquinone radical anion) forms of the thiazinoquinone with 
two binding sites (A and B) of dsDNA. 
In this kind of systems, the equilibrium constants for the interaction with the 
oxidized (KJ
ox) and reduced (KJ
rd) forms (J=A,B) can be related with the shift 
of the equilibrium potential of the CQJ/AQJ couple relative to the equilibrium 
potential of the unbounded thiazinoquinone (CQ1/AQ1) by means of the 
following relationship (Equation 3.7): 
 
   (3.7) 
 
 
Our data indicate that the semiquinone radical anion form is much more 
stabilized, relative to the quinone, when the interaction occurs in the site B than 
when the interaction occurs via the site A. 
Using equimolar concentrations of thiazinoquinone and dsDNA, the height of 
the peaks CQJ relative to the peak CQ1 (Figure 3.11) would be indicative of the 
intensity of the respective quinone-dsDNA interaction via the J-site. Our data 
                                                          
99 Doménech-Carbó, A.; Cebrián-Torrejón, G.; De Miguel, L.; Tordera, V.; Rodrigues, D.; 
Assad-Kahn, S.; Fournet, A.; Figadère, B.; Vázquez, R.; Popuon, E. Electrochim. Acta. 2014, 
115, 546-552. 
 









ox
QJ
rd
QJeq
Q1
eq
QJ ln
K
K
nF
RT
EE
46 
 
a) b)
c) d)
5 A
0.0              0.8               1.6                       0.8             1.6
E / V vs. Ag|AgCl E / V vs. Ag|AgCl
CQ1 CQ1
CQ1 CQ1
CQA CQA
CQA
AQ1 AQ1
AQ1
AQ1
CQB
AQB
CQB
CQB CQB
AQB
CQA
indicate that, under our experimental conditions, the intensity of the 
thiazinoquinone-dsDNA binding in the A-site decreases in the order 12> 14 > 
13  15, whereas the intensity of the thiazinoquinone-dsDNA binding in the B-
site decreases just in the inverse order.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Cyclic voltammograms at glassy carbon electrode, after semi-derivative 
convolution, of different 0.2 mM dsDNA (salmon testes) plus 0.3 mM 
thiazinoquinone solutions in 0.10 M Bu4NPF6/DMSO. a) 13; b) 14; c) 15; d) 12. 
Potential scan rate mV s1. 
 
This feature is in agreement with the competing effect exerted by the two sites 
for the interaction with thiazinoquinones (Figure 3.12). Interestingly, the 
relative order of A-site interaction of the conithiaquinones: 14 > 15, is in 
agreement with the relative cytotoxic ability with respect to human breast 
adenocarcinoma cells (MCF-7 line).80 This feature suggests a relation between 
the interaction with the binding site A and the cytotoxic activity of this family 
of compounds.  
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Figure 3.12 Square scheme for the electrochemistry of DMSO solutions of dsDNA 
plus the studied natural thiazinoquinones. 
 
3.3.4. Computational Studies 
Computational studies were performed on the molecular models of compounds 
12-15 (Figure 3.4) by using a combination of molecular dynamics (MD) and 
mechanic (MM) calculations with quantum-mechanical (QM) methods (PM7 
and DFT) (see the experimental section for details). 
The conformational and electronic properties of the compounds were 
investigated taking into account the reduction pathway of quinones (Q) to 
hydroquinones (QH2) in aqueous systems. This involves a sequence of steps in 
which reversible one-electron reduction reactions are followed by proton 
uptake reactions producing different intermediate species, as illustrated in 
Scheme 3.1. In the case of the natural thiazinoquinones 12-15, two possible 
protonated semiquinone radicals can be produced, named QH•i, QH•ii, 
respectively (Figure 3.13).  
Firstly, the conformational space of the starting neutral quinone species was 
sampled by applying a procedure including molecular dynamics (simulated 
annealing; SA), molecular mechanic (MM), and PM7 calculations. Obtained 
conformers were grouped into conformational families and ranked by their 
potential energy values. 
Secondly, the lowest energy conformer of each family was selected to be 
subjected to DFT full optimization. Finally, the DFT global minimum (GM) 
conformer of each compound was used to generate the reduced species Q•-, 
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QH•i, QH•ii, QH
-
i, QH
-
ii, and QH2, which were again subjected to DFT full 
optimization (Figure 3.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. Schematic representation of the formation of the two possible protonated 
semiquinones radicals in the reduction pathway of natural thiazinoquinones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. Q•-, QH•i, QH•ii, QHi-, QHii-, and QH2 species of 14 obtained from DFT 
calculations. 
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Table 3.3 Reaction energy values (ΔE; kcal/mol) calculated for the proposed 
reduction pathway (Scheme 3.1) considering the formation of the two possible 
semiquinone species. 
 
This allowed the calculation of the reaction energies (Ef(Prod.)  Ef(React.)) of 
each step of the reduction pathway reported in Scheme 3.1. Due to the 
formation of the two possible semiquinone species QH•i and QH•ii (Figure 
3.13), two different set of reaction steps were calculated for the reduction from 
Q to QH2 (Table 3.3; Figure 3.14). 
The first consideration that can be derived is that all compounds present a 
definite preference for the formation of one of the two possible semiquinone 
species, namely QH•i. (Step 2i vs Step 2ii; Table 3.3). This is likely due to the 
formation of a hydrogen bond between the SO2 group and the newly generated 
hydroxyl group of QH•i, which cannot be formed in the alternative QH•ii 
semiquinone (Figures 3.13 and 3.14). 
Regarding the relative compound potency in biological assays (Table 3.2), it 
has to be underlined that, since 12 and 13 were tested on different cancer cell 
lines, only 14 and 15 (tested on MCF-7 cells) can be directly compared.78-80 In 
this view, the rank order of the calculated reaction energies reported in Table 
3.3 for the whole reduction pathway (QQH2) reflects the activity order of the 
compounds (Table 3.2). Then, considering each reaction step (Scheme 3.1; 
Figure 3.13 and 3.14), the more active compound 14 shows higher propensity 
to acquire both the first and the second electron (Step 1 and 3, respectively) 
with respect to 15 (Table 3.3; Figures 3.4 and 3.5). On the contrary, the two 
protonation steps (Step 2 and Step 4) present more favorable reaction energies 
for 15 with respect to 14. In any case, according to the data reported in Table 
3.3, either the formation of the semiquinone species QH•i, either its subsequent 
Cmp (QQH2) Step 1 Step 2i Step 2.ii Step 3i Step 3ii Step 4i Step 4ii 
12 -773.6 -60.0 -326.4 -310.2 -54.8 -60.7 -332.4 -342.7 
13 -762.6 -50.4 -330.5 -313.2 -44.8 -56.4 -336.9 -342.6 
14 -769.4 -60.6 -323.2 -307.5 -53.0 -62.2 -332.6 -339.1 
15 -768.4 -53.0 -330.3 -313.6 -48.2 -55.1 -336.9 -346.7 
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reduction to hydroquinone is more favored for 14 (more active) with respect to 
15 (less active).  
It is noteworthy that the larger contribute to the overall reaction energy comes 
from the protonation steps and this is in agreement with the role played by 
semiquinone radical anion protonation on quinone reduction, as evidenced by 
our electrochemical studies. Actually, many variables can affect the 
protonation rate of the reduced species, which can significantly differ in a 
cellular environment. 
To further investigate the reactivity of the studied quinones and their 
semiquinone radical species, we calculated the vertical electron affinity (EA) 
of Q and QH•i and the ionization potential (IP) of Q•- and QH
•
i. The vertical 
EA measures the propensity of a molecule to acquire one electron without 
considering subsequent electronic and/or structural rearrangements which may 
drive the structure to a lower energy minimum (see the experimental section 
for details). At the same conditions, the vertical IP measures the propensity of a 
molecule to lose one electron. The resulting EA and IP values are reported in 
Table 3.4, together with the energy of the frontier orbitals of i) the neutral 
quinone Q (LUMO), ii) the radical anion Q•- (SOMO), and iii) the radical 
semiquinone QH•i (SOMO).  
 
Table 3.4 Calculated energy values (kcal/mol) of LUMO and SOMO orbitals, Vertical 
IP and vertical EA of the Q, Q•-, and QH•i species of natural thiazinoquinones. 
 
Cmp  
Q  Q•-  QH•i 
ELUMO 
Vertical 
EA    

 ESOMO Vertical  
IP 
 ESOMO Vertical  
IP 
Vertical 
 EA    
12 
-
86.383 
15.35 127.99  -34.074 66.8  -
121.47 
151.7 49.4 
13 
-
80.083 
24.82 93.77  -21.517 56.8  -
115.93 
151.5 39.2 
14 
-
89.452 
30.00 111.81  -32.442 69.2  -
127.72 
164.8 46.2 
15 
-
81.401 
22.52 93.85  -24.950 60.9  -
121.88 
158.2 41.2 
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The higher vertical EA and lower ELUMO energy of 14 with respect to 15, as 
well as, the higher vertical IP and lower ESOMO of its Q•- and QH•i radicals 
(Table 3.4), is in agreement with its lower reaction energy to form the 
semiquinone species (Table 3.3). Moreover, the higher propensity of 12, 
characterized by an IC50 of 3 µM on Jurkat cells (Table 3.2), to acquire, both, 
the first and the second electron (Step 1 and 3, respectively; Scheme 3.1; 
Table 3.3), agrees with i) the LUMO orbital energy of its Q form, and ii) the 
SOMO orbital energy and the vertical IP of its Q•- form (Table 3.4). By 
contrast, some considerations can be made comparing the relatively low 
vertical EA of the neutral quinone form of 12 (Table 3.4) to the calculated 
reaction energy for its one electron reduction (Step 1, Table 3.3). Indeed, 
contrarily to the vertical EA, the reaction energy takes in to account possible 
structural rearrangements after electron acquisition, by consequence, the results 
obtained for 12 revealed that the stability of its Q•- radical anion strongly 
depends on the ability to extend the electronic conjugation to the extra aromatic 
ring, as well as, the conformation of the long unsaturated alkyl chain (Figure 
3.6).  
Interestingly, the values reported in Table 3.4 also indicate that the protonated 
semiquinone radicals of all compounds (QH•i) are characterized by a marked 
vertical EA, significantly higher than the one of the corresponding parent 
quinone Q, following the same rank order of the relative activity of the 
compounds. This can account for their propensity to be reduced by superoxide 
anions, as resulted from electrochemical studies. 
Finally, we calculated the electrophilicity index100 of all compounds (ω; Table 
3.4) as a measure of their propensity to undergo a nucleophilic attack by 
biological molecules (DNA, protein, etc.). Interestingly, the resulting values 
resulted to be correlated to the intensity of the thiazinoquinone-dsDNA binding 
in the A-site calculated from voltammetric data.  
 
 
                                                          
100 Parr, R.G.; Szentplay, L.V.; Liu, S. J. Am. Chem. Soc. 1999, 121, 1922-1924.  
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3.4. Conclusions 
In conclusion, the extraction and the chemical analysis of Phallusia fumigata 
led to the isolation of the phallusiasterol C (6), a sulfated sterol, which is a 
possible modulator of the PXR nuclear receptor. Additionally, the 
electrochemical response of four natural cytotoxic thiazinoquinones (12-15), 
which were previously isolated and characterized from Aplidium species, has 
been investigated. The structural diversity of the metabolites, above reported, 
highlighted the fact that marine organisms continue to be satisfying sources of 
chemodiversity, associated with a very large array of pharmacological 
activities. These products provide a rich source of chemical diversity that can 
be used to design and develop new potentially useful therapeutic agents. 
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CHAPTER 4  
THE STEREOCHEMISTRY ASSIGNMENT: A GREAT 
CHALLENGE IN NATURAL PRODUCTS CHEMISTRY 
 
4.1. Introduction  
Molecular shape, symmetry and stereogenicity/chirality are the key concepts in 
natural products research. In the majority of cases, the planar structure 
elucidation is just the initial step for studying a natural product and many of its 
important aspects, e.g. the spectroscopic properties and reactivity, as well as 
the structure-activity relationship or protein-ligand interactions. The latter can 
only be studied after the structure of a compound, including the stereochemical 
configurations, has been well determined.101 Additionally, the bioactive natural 
product’s information, either used for structure-activity relationships or for 
retrosynthetic design for total synthesis, is precisely represented by its 3D 
structure. 
Generally, NMR, X-ray, synthetic approaches or chiroptical methods, the 
stereochemistry of natural products. However, in comparison to synthetic 
organic molecules, the stereochemical elucidation of natural products is 
significantly more impressive. In most cases, the number of available samples, 
which were isolated from an uncommon source or from species difficult to 
collect, is not sufficient. Moreover, while the absolute configuration of 
synthetic compounds can derive from the chiral educts stereo-information, 
nothing is known about the natural products configuration, unless related to 
other previously isolated and structurally related natural 
metabolites.102,103,104,105 
The determination of the relative configuration of the stereogenic centers, that 
in turn determines the conformational properties, is usually the starting point of 
                                                          
101 Mori, K. Chirality 2011, 23, 449–462. 
102 Molinski, T. F. Nat. Prod. Rep. 2010, 27, 321–329.  
103 Halabalaki, M.; Vougogiannopoulou, K.; Mikros, E.; Skaltsounis, A. L. Curr. Opin. 
Biotechnol. 2014, 25, 1–7. 
104 L.i, K.; Chung-Davidson, Y.; Bussy, U.; Li, W. Mar. Drugs. 2015, 13, 2694-2713. 
105 Allenmark, S. G. Nat. Prod. Rep. 2000, 17, 145–155. 
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the complete stereochemical assignment, including the absolute configuration 
of all the stereocenters. Many techniques and approaches have been developed 
and are nowadays available. Unfortunately, some of them are not always useful 
in natural products research; for example, X-ray structure determination leads 
to valid assignment in the case of samples forming suitable crystals. While for 
the over expressed biomacromolecules or synthetic compounds, this can be 
easily achieved, for a natural product it can be difficult, that is, an unusual 
chemical entity, could derive from an uncommon marine organism found in 
very small amont. The best solution regarding the stereochemical problem, 
would be the synthesis of all the possible stereoisomers for comparison of 
spectroscopic data. From a practical standpoint, this task is neither easily 
obtained nor necessary. The synthesis of ‘key’ segments for comparison, 
sometimes may help the stereostructure determination; usually, chemical 
degradations of the original metabolite to more simple compounds, which are 
more suitable to synthesis and/or spectroscopic analysis, are required, thus 
achieving microscale chemical transformations. NMR and CD based methods, 
assisted by empirical quantum mechanical prediction and/or chemical 
derivatization, became popular tools for stereochemistry analysis of natural 
products.106 
It should be kept in mind, that none of these techniques is predominant in the 
configuration assignments, however, each of them have their respective goals 
and limitations. Even today, when planar structures can be determined with 
microgram samples of molecules available, the stereochemistry assignment is 
still a great challenge for chemists and, sometimes, the proposed planar 
structure is completed years later. In fact, regardless of the compound contains 
only one or several stereocenters, natural products absolute stereostructures are 
solved on a case-by-case basis.  
                                                          
106 Petrovic, A. G.; Navarro-Vázquez, A.; Alonso-Gómez, J. L. Curr. Org. Chem. 2010, 14, 
1612-1628. 
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Sometimes we could not assign the stereochemistry of a new compound 
exclusively on the basis of classic methods, therefore we had to refer to other 
techniques that I am describing in this chapter. 
The following section talks about the problem of stereochemistry elucidation of 
acyclic scaffolds that I have been dealing with during my research. This 
problem is an important challenge in natural products chemistry and often, 
integrated approaches are needed, which require a number of rigorously 
acquired data obtained by combination of different tools, including chemical 
manipulation of the original molecule and organic synthesis.107 Databases of 
spectral information can be a great resource for stereostructure determination, 
too. For example, Kishi and coworkers, on the basis of their extensive 
experience on polyketides chemistry and synthesis, developed an NMR 
database of several motifs common to this natural products family. This data 
collection, known as the "universal NMR database (UDB)", allowed simplified 
protocols to be used for the relative and absolute configuration assignment of 
unknown polyketides without degradation and/or derivatization 
work.108,109,110,111 
 
4.2. Assignment of the Complete Stereochemistry of Phosphoeleganin 
Phosphoeleganin (16, Figure 4.1), a new phosphorylated polyketide, having a 
protein tyrosine phosphatase 1B (PTP1B) inhibitory activity, has been recently 
isolated from the Mediterranean ascidian Sidnyum elegans.112 By combination 
of spectroscopic analysis and microscale chemical degradation and/or 
derivatization, the stereostructure of this marine natural product has been 
established except for the absolute configuration of the carbinolic centers C11 
and C12. This provided two alternative stereostructures for the natural 
                                                          
107 Kobayashi; Y.; Lee, J.; Tezuka, K.; Kishi, Y. Org. Lett. 1999, 1, 2181-2184. 
108 Molinski, T. F.; Morinaka, B. I. Tetrahedron.2012, 68, 9307-91628. 
109Kobayashi, Y.; Tan, C.-H.; Kishi, Y. J. Am. Chem. Soc. 2001, 123, 2076-2078. 
110 Kishi, Y. Tetrahedron,2002, 58, 6239-6258. 
111 Higashibayashi, S.; Kishi, Y. Tetrahedron 2004, 60, 11977-11982 
112 Imperatore, C.; Luciano, P.; Aiello, A.; Vitalone, R.; Irace, C.; Santamaria, R.; Li, J.; Guo, 
Y.-W.; Menna, M. J. Nat. Prod. 2016, 79, 1144–1148 
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metabolite (Figure 4.1) corresponding to the 8S, 11S, 12R, 15S, 16R and 8S, 
11R, 12S, 15S, 16R configuration patterns. Therefore, my research was focused 
on absolute stereochemistry of C11/C12 determination, which led to the 
univocal 8S, 11S, 12R, 15S, 16R stereochemical assignment of 
phosphoeleganin, performed by combination of organic synthesis and chiral 
derivatization methods directed to the application of UDB concept. Indeed, the 
logic used in the universal NMR database approach is that, given a complex 
molecule composed of structural clusters of stereogenic centers connected with 
a number of methylene bridges, we can assume that (1) the structural properties 
of these clusters are inherent to the specific stereochemical arrangement of the 
(small) substituents on the carbon backbone and (2) the structural properties of 
these clusters are independent from the rest of molecule, when they are 
sufficiently separated from each other.109 In practice, the stereogenic subunits 
need only to be separated by two or more methylene groups so that they may 
be treated independently. 
 
 
 
Figure 4.1. Structure of phosphoeleganin (16)  
 
On this basis, we considered the C8-C12 stereocluster of phosphoeleganin, in 
which the S absolute configuration at C8 and the C11, C12-erythro relationship 
had been previously assigned.112 It was decided to compare the NMR chemical 
shifts of this stereocluster with those of synthetic compounds with known 
stereochemistry. We did not find any suitable model compound for comparison 
in the Kishi’s universal NMR database; therefore, we decided to prepare the 
four 8,9-erythro stereoisomers of 5,8,9-tetradecanetriol for this purpose. 
(Scheme 4.1). 
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Scheme 4.1. Synthesis of the four 8,9-erythro stereoisomers of 5,8,9-tetradecanetriol  
 
The cis-4-decenal (17) was converted to the (Z)-tetradec-8-en-5-ol (racemate) 
18 by coupling with n-BuLi and, then, treated with NMO and OsO4 1% to give 
a mixture of the four 8,9-erythro stereoisomers of 5,8,9-tetradecanetriol (rac-
19 and rac-20).  
Separation by reverse phase HPLC (Luna C18 MeOH/H2O 7:3) of the reaction 
mixture afforded two diastereoisomeric fractions (rac-19 and rac-20) as 
racemates. Both rac-19 and rac-20 were separately derivatized with three 
equivalents of (R)-methoxyphenylacetic acid (R-MPA) to afford, in each case, 
a diastereoisomeric mixture of tris-(R)-MPA esters, 21/22 and 23/24, 
respectively (Scheme 4.2). 
 
 
 
 
 
 
 
 
Scheme 4.2. Synthesis of the two diastereomers mixtures of triesters 21/22 and 23/24. 
a) EDC, DMAP, (R)-MPA, CH2Cl2, r.t. overnight. 
 
The four (R)-MPA derivatives were obtained as individual compounds by 
HPLC separation on silica gel column (hexane/EtOAc 85:15) and their 1H 
NMR spectra were registered. According to the approach proposed by Riguera 
group for the assignment of the relative configuration of acyclic sec/sec-1,n-
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diols by double derivatization,113,114 the chemical shift differences () in the 
couples 21/22 and 23/24 were calculated. It is to be noted that in our case it 
was not necessary to prepare the two (R and S) tris-MPA esters since the (S)-
MPA derivatives of 21 and 23 would be enantiomeric to the (R)-MPA 
derivatives of 22 and 24, respectively, and, consequently, their NMR chemical 
shifts would be identical. Δδ values calculation led to negative (or positive) Δδ 
(δH21-δH22 or δH22-δH21) values for C1- C5 protons and positive (or negative) 
Δδ values for C8-C14 protons in the 21/22 couple (Figure 4.2.a); on the 
contrary, all positive (or negative) Δδ (δH23-δH24 or δH24-δH23) values were 
obtained for C5- C8 protons in the 23/24 couple (Figure 4.2.b). Finally, 
comparison of the signs distribution in our couples with the trends noted by 
Riguera in every isomer of acyclic sec/sec-1,4-diols115 suggested a 5,8-anti, 
8,9-anti configuration in the 21/22 couple and a 5,8-syn, 8,9-anti configuration 
in the 23/24 couple. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Δδ signs distribution for the MPA esters of the couple 21/22 (a) and 23/24 
(b) 
 
Actually, as depicted in Figure 4.2, the patterns in the Δδ values sign 
distribution were not perfectly homogeneous, especially in the couple 21/22 
                                                          
113 Freire, F.; Manuel, J.; Quin˜oa´, E.; Riguera, R. J. Org. Chem. 2005, 70, 3778-3790. 
114 Seco, J.M.; Riguera, R. eMagRes. 2015, 4, 1–30. 
 
a) 
b) 
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where anomalies were detected for the protons whose signals are diagnostic. 
Combined shielding/deshielding effects of the MPA units enough close to each 
other possibly produce these anomalies, and increase the uncertainty degree in 
the stereochemical assignment.115  
Therefore, we considered to substantiate the (5S*,8S*,9R*) and the 
(5S*,8R*,9S*) relative configuration assignments in compounds 21/22 and 
23/24, respectively, by chemical means. 
To this purpose, we used a one-pot method116 to perform the stereoselective 
synthesis of tetrahydrofuran rings via the intermediary of cyclic ortho esters 
(19a and 20a) generated in situ from the enantiomerically pure tetradecane-
5,8,9-triols 19 and 20, derived from base-catalysed methanolysis of the tris-
(R)-MPA esters 21 and 23 (Scheme 4.3). 
 
 
 
 
 
 
 
Scheme 4.3. Base-catalysed hydrolysis of compounds 21 and 23. 
 
Treatment of 19 and 20 with trimethyl orthoacetate and 10 mol % PPTS 
followed by addition of catalytic BF3•Et2O, led to cyclization of the triols to 
provide excellent yields of 25 and 26. 
The ionization of the intermediate ortho ester, with a Lewis acid, led to a 
reactive acetoxonium species (19b). The reaction proceeded via exo cyclization 
of the reactive acetoxonium intermediate (19b), thereby inverting the 
configuration at C8. 
                                                          
115 Seco J. M.; Quiñoá, E.; Riguera, R. Chem. Rev. 2012, 112, 4603−4641. 
 
116 Zheng, T.; Narayan, R. S.; Schomaker, J. M.; Borhan, B. J. Am. Chem. Soc. 2005, 9 VOL. 
127, NO. 19, 6947 
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A trans and cis relationship across the THF rings in compounds 25 and 26, 
respectively, was then established by ROESY experiments. Particularly, strong 
dipolar couplings were observed between H5 and H8 in compound 26 whereas 
we did not detect any ROE correlation between these two protons for 
compound 25 (Figure 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.4. Preparation and stereoselective cyclization of tetradecane-5,8,9-triols 19 
and 20 
 
These results, combined with the stereoselective outcome of the cyclization 
reaction where the configuration at C8 is inverted, were in agreement with an 
anti-anti relative configuration in compound 19 and a syn-anti relative 
configuration in compound 20. Thus, the (5S*,8S*,9R*)- and the 
(5S*,8R*,9S*)- relative configurations were definitely assigned to the 
tetradecane-5,8,9-triols 19 and 20, respectively. The chemical characterization 
of compounds rac-19, rac-20, 25 and 26 was easily performed through spectral 
analysis and the data were reported in Table 4.1 and Table 4.2. 
Finally, the NMR data of the tetradecane-5,8,9-triols 19 and 20 were compared 
to those of the natural phosphoeleganin (16). This analysis evidenced that 
proton and carbon NMR resonances of 16 matched with those of 
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(5S*,8S*,9R*) tetradecane-5,8,9-triol (19) suggesting an 8,11-anti relative 
configuration in 16 (Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Key ROE correlations of compounds 25 and 26 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. 1H and 13C chemical shift values (CD3OD) of the triol portion of 16 and 
those of the triols 19 and 20. 
 
 
 
The absolute configuration at C8 in phosphoeleganin has been previously 
established as S. Thus, the assignment of the relative stereochemistry of C8-
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C11 segment as anti required an absolute configuration at C11 as S. 
Analogously, the C11-C12 anti configuration, previously established, too, 
required an absolute configuration at C12 as R. Therefore, the absolute 
stereochemistry of phosphoeleganin was completely determined as 8S, 11S, 
12R, 15S, 16R. 
In conclusion, these data confirmed the anti-anti relative configuration of rac-
19 and a syn-anti relative configuration of rac-20 as previously established by 
CDA derivatization method. 
 
 
 
 
Table 4.1. 1H (700 MHz) and  13C NMR (175 MHz) data for rac-19 and rac-
20 in CD3OD 
rac rac
Pos C 
H  
(mult, J in Hz) 
C 
H  
(mult, J in Hz) 
1 14.1 0.92 (t, 7.6) 14.1 0.92 (t, 7.6) 
2 28.7 1.32 a -1.43 a 28.7 1.33 a -1.44 a 
3 32.8 1.32 a 32.8 1.32 a 
4 37.9 1.42 a -1.46 37.9 1.42 a -1.46 a 
5 72.9 3.53 72.1 3.55 
6 34.6 1.39 a - 1.72 34.3 1.53 a -1.60 a 
7 29.6 1.38 a - 1.80 29.3 1.48 a – 1.70 a 
8 76.3 3.34 75.6 3.37 
9 75.9 3.36 75.6 3.38 
10 33.4 1.36 a – 1.60 a 33.4 1.36 a – 1.60 a 
11 26.4 1.33 a -1.54 26.4 1.33 a -1.54 a 
12 32.8 1.32 a 32.8 1.32 a 
13 23.7 1.34 a 23.7 1.34 a 
14 14.1 0.92 (t, 7.6) 14.1 0.92 (t, 7.6) 
aPartially overlapped by other resonances 
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Table 4.2. 1H (700 MHz) and  13C NMR (175 MHz) data for 25 and 26 in 
CD3OD  
 
Pos C  
H  
(mult, J in Hz) 
C  
H  
(mult, J in Hz)  
1 14.1 0.87 (t, 7.6) 14.1 0.87 (t, 7.6) 
2 22.8 1.30 a  22.9 1.30 a 
3 28.4 1.31 a - 1.25 28.5 1.31 a-1.25 
4 35.5 1.38 a -1.56 35.5 1.40 a -1.56 a 
5 79.6 3.88 80.1 3.81 
6 32.4 1.44 a - 1.98 31.2 1.44 a -1.92 a 
7 28.4 1.58 a - 1.96 27.8 1.62 a – 1.89 a 
8 79.3 3.98 79.6 3.91 
9 75.7 4.86 75.9 4.87 
10 31.1 1.53 a  31.2 1.56 a  
11 31.9 1.27 a  31.9 1.27 a  
12 25.6 1.28 a 25.2 1.28 a 
13 22.8 1.30 a 22.6 1.29 a 
14 14.1 0.87 (t, 7.6) 14.1 0.87 (t, 7.6) 
aPartially overlapped by other resonances 
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4.3. Conclusions 
The assignment of a natural product’s absolute configuration is a laborious task 
and mistakes can occur as well. When a novel natural product is ready for 
stereochemical assignment, its chemical structure should be carefully studied 
and its physicochemical properties considered before a preferable method is 
chosen. So, the configurational assignment in natural products depends on the 
skills and on the tenacity of the chemist, who must have a great power of 
observation and extreme perseverance. From these studies, several issues may 
arise. For example: are all the natural products pure enantiomers? Can a single 
enantiomer of a biomolecule be always responsible for its bioactivity? Recent 
results have shown that bioactive natural products are not always 
enantiomerically pure, the stereochemistry–bioactivity relationships are 
complicated and the existing dogma about an enantiomer being bioactive must 
be modified. Additionally, several studies show the complexity and the 
importance of the stereochemistry for the expression of bioactivity of natural 
products. Kenji Mori, a well-known researcher in the natural products 
stereochemistry field, recently pointed out that the so far accepted view 
regarding only a certain enantiomer responsible for the activity, is not a fixed 
rule in nature anymore. Furthermore, other examples show different 
relationships between configuration and bioactivity, e.g. both enantiomers are 
needed for the bioactivity, or even in the same genus, different species accept 
different enantiomers.  
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CHAPTER 5 
DEVELOPMENT OF NATURE INSPIRED ANTIMALARIAL 
HITS POSSESSING THE THIAZINOQUINONE 
PHARMACOPHORE 
 
5.1. Introduction  
Part of my work was also focused on the development of nature inspired 
antimalarial hits possessing the thiazinoquinone pharmacophore. 
The starting point of this research was the identification of the thiazinoquinone 
scaffold as a new chemotype active against P. falciparum based on studies on 
marine-derived quinone compounds with antiplasmodial activity 117,118,119,120 
which inspired the design and synthesis of a series of new derivatives120-121 
(Figure 5.1). 
 
 
 
 
 
 
  
Figure 5.1.  Structures of aplidinones A and B and their synthetic analogues 
 
In collaboration with the Department of Biomedical, Surgical and Dental 
sciences (University of Milan), some previously synthesized thiazinoquinones 
                                                          
117 Laurent, D.; Jullian, V.; Parenty, A.; Knibiehler, M.; Dorin, D.; Schmitt, S.; Lozach, O.; 
Lebouvier, N.; Frostin, M.; Alby, F.; Maurel, S.; Doerig, C.; Meijer, L.; Sauvain, M. Bioorg. 
Med. Chem. 2006, 14, 4477-82. 
118 Longeon, A.; Copp, B.R.; Roué, M.; Dubois, J.; Valentin, A.; Petek, S.; Debitus, C.; 
Bourguet-Kondracki, M. Bioorg. Med. Chem. 2010, 18, 6006-11. 
119 Davis, R. A.; Duffy, S.; Fletcher, S.; Avery, V.M.; Quinn, R. J. J. Org. Chem. 2013, 78, 
9608-13. 
120 Aiello, A.; Fattorusso, E.; Luciano, P.; Menna, M.; Calzado, M. A.; Munoz, E.; Bonadies, 
F.; Guiso, M.; Sanasi, M. F.; Cocco, G.; Nicoletti, R. Bioorg. Med. Chem. 2010, 18, 719-727.  
121 Imperatore, C.; Persico, M.; Aiello, A.; Luciano, P.; Guiso, M.; Sanasi, M. F.; Taramelli, 
D.; Parapini, S.; Cebrián-Torrejón, G.; Doménech-Carbó, A.; Fattorusso, C.; Menna, M. RSC 
Advances, 2015, 5, 70689-70702.  
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have been tested. These compounds showed an interesting in vitro antimalarial 
activity, also on chloroquine-resistant strains of P. falciparum (IC50 < 1μM), 
although some of them were strongly cytotoxic. Some structural requirements 
critical for both the antiplasmodial activity and cytotoxicity were then revealed. 
In particular, it has been seen that both the regiochemistry of dioxothiazine ring 
and the type of the substituent on the quinone play an important role on the 
antiplasmodial effects whereas, in the active regioisomers (RB), the presence 
and/or the length of the side chain distinguishes the antiplasmodial activity 
from the cytotoxicity. Two new antimalarial hits, compounds 28 and 33, were 
thus identified, with an IC50 in the low micromolar range and non-toxic
121 
(Figure 5.2). 
 
 
 
 
 
 
Figure 5.2. New marine inspired thiazinoquinone hits (28, 33) 
 
Additionally, in order to rationalize the structure-activity relationships (SARs), 
an integrated approach based on computational and electrochemical studies 
was performed. These studies were carried out by a further collaborating 
external research group. 
These studies led to the hypothesis that the antiplasmodial activity of 
thiazinoquinones is related to their capacity to form toxic semiquinone species, 
with the thiazinoquinone ring system planarity favoring the reductive 
activation of parent quinone and the length of alkyl side chain distinguishing 
the antiplasmodial from the cytotoxic activity121. 
Accordingly, the electrochemical studies strongly evidenced the relationship 
between the antiplasmodial activity and an intense interaction with Fe(III)-
heme, achieved through the formation of an adduct between the semiquinone 
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species and Fe(III)-heme.122 The results obtained by the combination of these 
studies allowed us to identify new hits candidates. 
The newly identified hits compounds 28 and 33 were used as starting point for 
the synthesis and/or chemical modification of additional analogues, with 
improved pharmacological proprieties and featuring this chemical scaffold. 
The structural determination of the new compounds was univocally performed 
through NMR spectroscopy and mass spectrometry. 
In addition, studies on the reaction intermediates and their collateral products 
have been performed through an extensive spectroscopic analysis in order to 
improve the yields and/or to expand the chemical diversity.  
The final aim of my research was to produce a pool of new compounds to be 
tested for their antiplasmodial and cytotoxic activity. 
Based on the obtained SAR results for the previously developed antiplasmodial 
thiazinoquinone compounds,120-121 I performed the synthesis of new analogues 
containing: 
1. a double bond in the thiazine ring 
2. different alkyl side chains 
3. different benzyl side chains 
5.2. Synthesis of derivatives with a double bond in dioxothiazine ring  
A first chemical modification has been the introduction of a double bond in 
dioxothiazine ring. This modification has been inspired by data about 
Tiaplakortones A and B, reported in literature123 (Figure 5.3). 
 
 
Figure 5.3. Tiaplakortones A and B 
                                                          
122 Doménech-Carbó, A.; Maciuk, A.; Figadère, B.; Popuon, E.; Cebrián-Torrejón, G. Anal. 
Chem. 2013, 85, 4014-4021.  
123 Davis, R. A.; Duffy, S.; Fletcher, S.; Avery, V. M.; Quinn, R. J.   J. Org. Chem., 2013, 78 
(19), 9608–9613 
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It has been evidenced that the presence of a double bond in the thiazinoquinone 
nucleus, produced in these compounds an increasing of the antiplasmodial 
activity. Moreover, this modification has also been related to computational 
studies, performed on the compounds of the previous series (Figure 5.1), that 
have evidenced that thiazinoquinone ring system planarity plays an important 
role in the antiplasmodial activity.121 In particular, it is shown that the increase 
of the antiplasmodial activity, in relation to the presence of the double bond, 
seems to be correlated to a greater planarity and rigidity of the thiazinoquinone 
nucleus.  
In order to perform this modification, the derivatives 28, 30, 33 and 34 with an 
interesting antiplasmodial activity121, were treated with a solution of potassium 
hydroxide 1 M for 3h at room temperature.124 
Subsequently, the reaction mixture was diluted with hydrochloric acid 2 M; 
then extracted with ethyl acetate and purified by column chromatography on 
silica gel (EtOAc /hexane=6:4) to afford the pure compounds 39, 41, 42 and 
only the compound 40 as collateral product (Scheme 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
124 Chia, E. W.; Pearce, A. N.; Berridge, M. V.; Larsen, L.; Perry, N. B.; Sansom, C. E.; 
Godfrey, C. A.; Hanton, L. R.; Lu, G. L.; Walton, M.; Denny, W. A.; Webb, V. L.; Copp, B. 
R.; Harper, J. L. Bioorg. Med. Chem. 2008, 16, 9432-9442. 
Scheme 5.1. Synthesis of thiazinoquinones 39–42 
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The spectroscopic data have evidenced that the reaction performed on the 
compound 28 has produced the compound 40, in which beside the formation of 
the double bond, the substitution of methoxy group with hydroxyl group 
occurred. This collateral reaction has not been observed in the reaction of the 
compound 30 which leads only to the formation of the compound 41, probably 
because of the longest steric hindrance of the side chain. However, this is an 
aspect that needs further investigations.  
The structures of the new compounds 39-42 were established on the basis of 
the spectroscopic analysis of the starting compounds120-121 28, 30, 33 and 34, as 
described below. The molecular formula of the compound 40 was determined 
to be C10H9NO5SNa by (+)-HRESIMS of the pseudo-molecular [M +Na]
 + ion 
peak at m/z 278.0098. The spectral data (Table 5.1) obtained for compound 40 
were nearly identical to those of 28 apart from the presence of two downfield 
olefin signals resonating in the proton spectrum at δH 6.19 (d, J=8.9, 1H, H-2), 
and δH 7.04 (d, J=8.9, 1H, H-3). These resonances were assigned to one 
disubstituted double bond, based on the two down-field resonances present in 
the 13C NMR spectrum at δC 109.1 (CH), 130.3 (CH). Furthermore, the 
spectroscopic data 1H and 13C NMR have not evidenced the presence of the 
methyl signal observed in the compound 28, thus suggesting that during the 
oxidation reaction, beside the formation of the double bond in the 
dioxothiazine ring, in the compound 40 the substitution of methoxy group with 
hydroxyl group occurred. 
The chemical characterization of compound 41 was easily performed through 
spectral analysis (Table 5.1). The molecular formula of the compound 41 was 
determined to be C17H23NO5SNa on the basis of (+)-HRESIMS of the pseudo-
molecular ion [M +Na] + at m/z 376.1193, differing from that of 30 only for the 
additional unsaturation. Analysis of 1H and 13C spectra confirmed that the only 
difference between 41 and 30 was the presence of a double bond in 41. 
Analogously, the structures of the oxidized compounds 39 and 42 were easily 
established on the basis of spectroscopic analysis (Table 5.2). 
The pharmacological results have shown that the compound 40 was completely 
inactive compared to the starting compound 28. The lack of any activity can be 
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due to the presence of hydroxyl group that might be subjected to a tautomeric-
equilibrium which could cause a significant deviation from the planarity of 
benzoquinone ring. Currently, in collaboration with the research group of Prof. 
Fattorusso (University of Naples “Federico II”, Department of Pharmacy), the 
compound 40 is still subject of computational studies in order to clarify the 
effects of a possible tautomeric equilibrium on the antiplasmodial activity 
 
 
 
 
 
 
 
Table 5.1. NMR data of compounds 40 (CD3OD) and 41 (DMSO-d6).  
 40 41 
Pos. δC 
δH, mult. 
(J in Hz) 
HMBC δC 
δH, mult. 
(J in Hz) 
HMBC 
1 - - - - - - 
2 109.1 6.19 d (8.9) 3, 8a, 8 111.9 6.41 d (8.9) 3, 8, 8a 
3 130.3 7.04 d (8.9) 2, 4a 130.8 7.02 d (8.9) 2, 4a 
4 - - - - - - 
4a 137.7 - - 138.9 - - 
5 180.6 - - 175.9 - - 
6 158.8 - - 154.8 - - 
7 122.6 - - 138.9 - - 
8 180.2 - - 181.6 - - 
8a 114.4 - - 110.1 - - 
1’ 17.0 2.45, q (7.5) 6, 7, 8, 2’ 23.4 2.46, t (7.5) 6, 7, 8  2’ 
2’ 13.6 1.03, t (7.5) 5, 6, 7, 1’ 28.8 1.43, m  
3’ - - - 29.5 1.26 7’ 
4’-5’ - - - 29.1 1.26  
6’ - - - 31.7 1.24  
7’ - -  22.3 1.27  
8’ - -  13.5 0.87, t, (7.5)  
OCH3 - -  61.1 3.88  
4-NH - - 7, 8, 1’ - 11.1, br s  
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Table 5.2. NMR data of compounds 39 and 42 in CD3OD.  
 39 42 
Pos. δC 
δH, mult. 
(J in Hz) 
HMBC δC 
δH, mult. 
(J in Hz) 
HMBC 
1 - - - - - - 
2 112.2 6.40 d (8.9) 3, 8a, 8 112.1 6.40 d (8.9) 3, 8, 8a 
3 131.7 7.13 d (8.9) 2, 4a 131.6 7.11 d (8.9) 2, 4a 
4 - - - - - - 
4a 140.8 - - 139.8 - - 
5 180.9 - - 175.9 - - 
6 142.0 - - 149.0 - - 
7 139.9 - - 137.0 - - 
8 180.7 - - 181.7 - - 
8a 114.6 - - 112.1 - - 
1’ 20.7 2.47, q (7.5) 2’, 6, 7, 8 20.2 2.51, q (7.5) 2', 6,7,8 
2’ 12.1 1.09, t (7.5) 1' 12.8 1.09, t (7.5) 1' 
1” 180.6 -  181.3 -  
2” 40.8 -  40.5 -  
Me 27.6 1.32, s  27.8 1.28, s  
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5.3. Synthesis of derivatives with different alkyl side chains 
The newly identified hit compound 28 was used as starting point for the 
synthesis of additional analogues, compounds 46-51 with improved 
pharmacological proprieties and featuring different alkyl chains (Scheme 5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5.2. Synthesis of thiazinoquinones 46-51 
 
A first series of new methoxy-derivatives have been prepared using a synthetic 
approach very similar to that adopted for the synthesis of the compound 28.120 
In particular, the first synthetic step has been the lithiation of the commercially 
available 1,2,4-trimethoxybenzene (43) and then the alkylation with three alkyl 
bromides to obtain the corresponding 1,2,4-trimethoxy-3 alkylbenzenes 44-R1, 
44-R2, and 44-R3 with good yields (80%, 76%, and 77%, respectively). Then, 
the oxidation of 44-R1, 44-R2, and 44-R3 with cerium ammonium nitrate 
(CAN) gave the quinones 45-R1 (65% yield), 45-R2 (65% yield), and 45-R3 (74 
% yield), respectively. Finally, the condensation reaction with hypotaurine 
provided the new thiazinoquinones 46-51. This last reaction is not highly 
regioselective, and produces for each quinone two regioisomers in a ratio of 
8:2 in favor of regioisomer B (RB); however, it is simple and cheap in order to 
obtain the required scaffold. Moreover, the formation of both regioisomers also 
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enlarges the pool of compounds to include in pharmacological studies. In 
addition, the regioisomers can be easily separated by HPLC in the same 
conditions, and then identified by spectroscopic techniques.  
The chemical characterization of compounds 46-51 was easily performed 
through spectral analysis (Tables 5.3, 5.4), referring to the NMR spectral 
assignments made for 27 and 28.120 Actually, carbon and proton resonances 
relative to the bicyclic nucleus of the couples of compounds 46/47, 48/49 and 
50/51 were virtually identical to those of compounds 27 and 28, respectively, 
thus defining the structures 46-51 as reported in Scheme 5.2.  
 
 
 
 
Table 5.3. NMR data of compounds 46-49. 
 46 47 48 49 
Pos. δC 
δH, mult. 
(J in Hz) 
δC 
δH, mult. 
(J in Hz) 
δC 
δH, mult. 
(J in Hz) 
δC 
δH, mult. 
(J in Hz) 
1 - - - - - - - - 
2 48.6 3.29 m 48.7 3.28 m 48.8 3.29 m 48.7 3.28 m 
3 39.8 4.06 m 39.5 4.06 m 39.7 4.06 m 39.5 4.06 m 
4 - - - - - - - - 
4a 144.2 - 142.8 - 144.3 - 142.8 - 
5 179.5 - 176.5 - 179.4 - 176.5 - 
6 127.7 - 152.9 - 127.7 - 152.9 - 
7 157.6 - 138.8 - 157.6 - 138.8 - 
8 174.1 - 178.1 - 174.1 - 178.1 - 
8a 109.1 - 110.2 - 109.0 - 110.2 - 
1’ 34.9 2.28, d (7.3) 34.8 2.38, d (7.3) 22.9 2.38, t (7.5) 23.5 2.47, t (7.5) 
2’ 28.1 1.75 m 28.3 1.87 28.1 1.45,m 28.8 1.43, m 
3’ 22.6 0.86, d (6.7) 22.5 0.89, t (7.5) 29.6 1.40, m 29.5 1.38, m 
4’ 22.6 0.86, d (6.7) 22.5 0.89, t (7.5) 13.9 0.88 t (7.5) 13.8 0.86 t (7.5) 
OCH3 62.2 4.23 s 60.6 3.91 s 62.1 4.26 s 60.7 3.92 s 
NH - 6.71, brs - 6.50, brs - 6.81, brs - 6.40, brs 
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Table 5.4. NMR data of compounds 50-51. 
 50 51 
Pos. C 
H, mult. 
(J in Hz) 
C 
H, mult. 
(J in Hz) 
1 - - - - 
2 48.7 3.28, m 48.9 3.30, m 
3 39.7 4.05, m 39.8 4.02, m 
4 - - - - 
4a 144.6 - 142.5 - 
5 180.4 - 176.5 - 
6 126.7 - 153.5 - 
7 158.6 - 137.8 - 
8 173.2 - 179.0 - 
8a 109.5 - 110.5 - 
CH2 30.4 2.29, d (7.2) 31.4 2.23, d (7.1) 
1’ 37.7 1.39, m 38.1 1.55, m 
2’-6’ 33.2 1.56-0.92, m 33.4 1.53-0.95, m 
3’-5’ 26.0 1.66-1.14, m 26.2 1.66-1.15, m 
4’ 26.1 1.60, m 26.7 1.60, m 
OCH3 62.3 4.22 s 60.8 3.88 s 
NH - 6.74, brs - 6.45, brs 
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5.4. Synthesis of benzyl-methoxy thiazinoquinones  
The previous synthetic protocol has been modified to prepare the benzyl 
derivatives (56-61; Scheme 5.3).  
This synthesis has been inspired by date reported in literature about 
benzylmenadione, a naphthoquinone, whose antimalarial activity has been 
related to its redox proprieties, probably due to electronic effects of its benzyl 
chain.125,126 
 
 
 
 
Figure 5.4. Putative redox cascade reactions accounting for the observed antimalarial 
activity of 3-benzylmenadione derivatives. 
 
Concerning the antimalarial mode of action, it was proposed that the lead 
benzyl naphthoquinones are initially oxidized at the benzylic chain to benzoyl 
naphthoquinones in a heme-catalyzed reaction within the digestive acidic 
vesicles of the parasite. The major putative benzoyl metabolites were then 
found to function as redox cyclers: (i) in their oxidized form, the benzoyl 
metabolites are reduced by NADPH in glutathione reductase-catalyzed 
reactions within the cytosols of infected red blood cells; (ii) in their reduced 
                                                          
125 Muller, T.; Johann, L.; Jannack, B.; Bruckner, M.; Lanfranchi, D. A.; Bauer, H.; Sanchez, 
C.; Yardley, V.; Deregnaucourt, C.; Schrevel, J.; Lanzer, M.; Schirmer, R. H.; Davioud-
Charvet, E.  J. Am. Chem. Soc. 2011, 133, 11557–11571. 
126 Bielitza, M.; Belorgey, D.; Ehrhardt, K.; Johann, L.; Lanfranchi, D. A.; Gallo, V.; 
Schwarzer, E.; Mohring, F.; Jortzik, E.; Williams, D. L.; Becker, K.; Arese, P.; Elhabiri, M.; 
Davioud-Charvet, E. Antioxid. Redox Sign. 2015, 22, 1337-1351. 
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forms, these benzoyl metabolites can convert methemoglobin, the major 
nutrient of the parasite, to indigestible hemoglobin (Figure 5.4). Therefore, on 
the basis of this hypothesis, the benzyl-methoxy derivatives were prepared.  
In order to improve the yields, the previous synthetic protocol has been 
modified. Regarding the synthetic approach, firstly, it was utilized the 
benzaldehyde instead of the benzylic halide, which was added to the lithiated 
of 1,2,4 trimethoxybenzene solution (52) giving rise to the secondary benzylic 
alcohols (53-R4, 53-R5, 53-R6), followed by their reduction (54-R4, 54-R5, 54-
R6), using trifluoracetic acid in dichloromethane and then 
triethylsilane.127,128,129 After that, as in the previous protocol, an oxidation and 
finally a condensation with hypotaurine took place. The last reaction is not 
highly regioselective in this case too (Scheme 5.3). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5.3. Synthesis of thiazinoquinones 56-61 
 
Also in this case, all regioisomers 56-61 were isolated as individual compounds 
by HPLC separations in same conditions. Their chemical characterization 
                                                          
127 Spyroudis, S. Molecules. 2000, 5, 1291-1330 
128 Waterlot, C.; Couturier, D.; De Backer, M.; Rigo, B. Can. J. Chem. 2000, 78, 1242-1246  
129 Farmer, J. L.; Froese, R. D. J.; Lee-Ruff, E.; Organ M. G. Chem. Eur. J. 2015, 21, 1888-
1893. 
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(Tables 5.5, 5.6) was readily identified by comparison of their spectroscopic 
data with those reported in literature, for compounds 27 and 28. 104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.5. NMR data of compounds 56-57. 
 56 57 
Pos. C 
H, mult. 
(J in Hz) 
C 
H, mult. 
(J in Hz) 
1 - - - - 
2 48.3 3.24, m 49.3 3.24, m 
3 40.0 4.02, m 40.6 3.99, m 
4 - - - - 
4a 144.3 - 142.6 - 
5 179.2 - 176.1 - 
6 127.0 - 152.9 - 
7 157.5 - 136.0 - 
8 173.1 - 178.1 - 
8a 109.2 - 110.5 - 
CH2 28.7 3.71, s 29.8 3.80, s 
1’ 138.9 - 138.1 - 
2’-6’ 128.8 7.19, d, (7.3) 130.0 7.28, d, (7.3) 
3’-5’ 128.8 7.24, t (7.3) 129.0 7.22, t, (7.3) 
4’ 126.8 7.17, t (7.3) 127.2 7.15, t, (7.3) 
OCH3 63.3 4.29 s 62.0 3.87 s 
NH - 6.74, brs - 6.45, brs 
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Table 5.6. NMR data of compounds 58-61. 
 58 59 60 61 
Pos. C 
H, mult. 
(J in Hz) 
C 
H, mult. 
(J in Hz) 
C
H, mult. 
(J in Hz)
C
H, mult. 
(J in Hz)
1 - - - - - - - - 
2 48.2 3.24, m 49.0 3.23, m 48.3 3.24, m 49.3 3.24, m 
3 40.1 4.02, m 40.4 3.99, m 40.0 4.02, m 40.6 3.99, m 
4 - - - - - - - - 
4a 144.2 - 142.5 - 144.3 - 142.6 - 
5 179.1 - 176.2 - 179.2 - 176.1 - 
6 127.2 - 152.8 - 127.0 - 152.9 - 
7 157.3 - 136.1 - 157.5 - 136.0 - 
8 173.0 - 178.0 - 173.1 - 178.1 - 
8a 109.1 - 110.4 - 109.2 - 110.5 - 
CH2 28.6 3.71, s 29.8 3.80, s 28.6 3.77, s 29.8 3.85, s 
1’ 137.8 - 137.8 - 142.3 - 142.1 - 
2’-6’ 126.8 7.19, d, (8.3) 126.4 7.21, d, (8.3) 127.8 7.30, d, (8.3) 127.6 7.20, d, (8.3) 
3’-5’ 127.6 7.24, d (8.3) 127.3 7.25, d, (8.3) 126.4 7.49, d (8.3) 126.5 7.24, d (8.3) 
4’ 133.2 - 133.1 - 128.8 - 128.9 - 
CF3 - - - - 124.2  124.1  
OCH3 63.2 4.29 s 62.1 3.94 s 63.1 4.29 s 63.3 3.93 s 
NH - 6.80, brs - 6.45, brs - 6.80, brs - 6.55, brs 
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5.5. Pharmacological activity  
In collaboration with the Department of Biomedical, Surgical and Dental 
sciences (University of Milan), the synthetic analogues of natural 
thiazinoquinones have been tested for their in vitro antiplasmodial activity 
against both chloroquine (CQ)-sensitive (D10) and -resistant (W2) strains of P. 
falciparum; cytoxicity against human microvascular endothelial (HMEC-1) 
cells has been also evaluated. 
Regarding the oxidized compounds 39-42, they haven’t shown the expected 
effects on the antiplasmodial activity (Table 5.7). In fact, all compounds with 
the added insaturation resulted less active than the starting related 
compounds120 (28, 30, 33, 34). However, while the amide-derivatives 39 and 
42 have shown only a slight decrease of the antiplasmodial activity compared 
to the starting compounds 33-34, the methoxy-derivative 41 resulted 
significantly less active than the starting compound 30. In the case of 
compound 40 (Table 5.7), the lack of any activity can be related to the 
tautomeric equilibrium due to the presence of the free hydroxyl group that 
might cause a significant deviation from the planarity of benzoquinone ring. 
These differences underline the key role of the type of substituent on the 
quinone, which we are trying to understand through computational studies.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.7. Pharmacological activity of compounds 39-42  
Compound 
D10a 
IC50 (µM) 
W2a 
IC50 (µM) 
HMEC-1a 
IC50 (µM) 
39 0.72 2.1 2.3 
40 NA NA NA 
41 8.9 NA NA 
42 3.5 7.4 NA 
aCloroquine (CQ) has been considered as positive control (D10 IC50 = 0.04 ± 0.01; 
W2 IC50 = 0.54 ± 0.28; not cytotoxic). Data are the mean ± SD of three different 
experiments in duplicate; NA: not active (IC50 > 10 M against D10 and W2 
strains of P. falciparum and IC50 > 100 µM against HMEC-1) 
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Moreover, the pharmacological screening on the two regioisomers series with 
different alkyl side chains (46-51), have confirmed, above all, the critical role 
of the regiochemistry on the antiplasmodial effects since the regioisomers 46, 
48, 50 resulted completely inactive. 
In series of the active regioisomers 47, 49, 51 (Table 5.8), although we have 
not obtained a compound with improved proprieties compared to our starting 
hit 28, these results have shown that the presence of a bulky side chain 
increases the cytotoxic activity, even if a linear correlation length-activity has 
not been evidenced, suggesting that a particular "shape" of the side chain is 
required. 
 
 
 
 
 
 
 
 
 
 
 
 
The most interesting pharmacological results were obtained for the compound 
57. It exhibited the highest antiplasmodial activity (less than 1 micromolar) and 
an acceptable selectivity index, thus representing a new hit with improved 
proprieties compared to the starting hit 28 (Table 5.9).  
In addition, comparison of the antiplasmodial activity of this compound to 
those of the totally inactive compounds 56, its regioisomer, and 55-R4, lacking 
the thiazine ring, strongly evidenced the crucial role of the dioxothiazine ring 
for the antiplasmodial effect as well as the importance of the regiochemistry. 
 
 
Table 5.8. Pharmacological activity of compounds 50-55 
Compound 
D10a 
IC50 (µM) 
W2a 
IC50 (µM) 
HMEC-1a 
IC50 (µM) 
46 NA NA NA 
47 1.3 2.7 26.8 
48 NA NA NA 
49 1.7 2.5 40.2 
50 NA NA NA 
51 2.37 3.03 3.91 
aCloroquine (CQ) has been considered as positive control (D10 IC50 = 0.04 ± 
0.01; W2 IC50 = 0.54 ± 0.28; not cytotoxic). Data are the mean ± SD of three 
different experiments in duplicate; NA: not active (IC50 > 10 M against D10 
and W2 strains of P. falciparum and IC50 > 100 µM against HMEC-1) 
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As regard to the mechanism of action of the thiazinoquinones, certainly it is 
related to their redox proprieties. It would seem related to the possibility to 
form stable toxic semiquinone species acting as “subversive substrates”,121 but 
it still remains unclear. Further experiments were carried out on the novel hit 
compound 57, as described below. 
The hemolysis of red blood cells (RBCs), both P. falciparum infected and 
uninfected, was evaluated. The activity of the compound 57 was compared to 
its inactive regioisomer 56 in each experiment. The hemolysis percentage was 
monitored with a spectrophotometer (OD 405) measuring the absorbance of the 
hemoglobin released in the supernatant of the uninfected and infected RBCs. 
As shown in the Table 5.10, the release of hemoglobin was very low both in 
control RBCs and in those treated with 56 and 57 up to a concentration of 
20microg / ml. This demonstrated the almost complete absence of hemolysis in 
both infected and non-infected red blood cells. 
A second experiment was performed in order to evaluate the formation of 
methemoglobin, the major parasites nutrient. This experiment was carried out 
using the algorithm of Winterbourn and was performed in both PBS and in 
complete cell culture medium used for the growth of the parasite. 
Table 5.9. Pharmacological activity of compounds 56-61 and 55-R4 
Compound 
D10a 
IC50 (µM) 
W2a 
IC50 (µM) 
HMEC-1a 
IC50 (µM) 
56 NA NA NA 
57 0.60 0.70 17.6 
58 NA NA NA 
59 1.63 1.90 8.5 
60 NA NA NA 
61 5.05 5.02 20.4 
55-R4 NA NA NA 
aCloroquine (CQ) has been considered as positive control (D10 IC50 = 0.04 ± 0.01; W2 
IC50 = 0.54 ± 0.28; not cytotoxic). Data are the mean ± SD of three different experiments 
in duplicate; NA: not active (IC50 > 10 M against D10 and W2 strains of P. falciparum 
and IC50 > 100 µM against HMEC-1) 
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As reported in Table 5.11, both 56 and 57 induced the formation of 
methemoglobin, with 57 even acting at low concentrations.  
Table 5.11. Formation of methemoglobin 
56 in PBS 1%O2a 20%O2a 57 in PBS 1%O2a 20%O2a 
Conc. µM %OXY %META %OXY %META Conc. µM %OXY %META %OXY %META 
0.93  98,30 1,70 97,06 2,94 0.93  39,30 60,70 42,29 57,71 
1.86  95,19 4,81 93,85 6,15 1.86  26,44 73,56 27,47 72,53 
3.72 89,83 10,17 88,06 11,94 3.72 16,71 83,29 17,21 82,79 
7.44 80,31 19,69 79,03 20,97 7.44 11,05 88,95 11,71 88,29 
14.88 67,26 32,74 64,96 35,04 14.88 8,63 91,37 8,48 91,52 
29.76 51,14 48,86 49,53 50,47 29.76 8,47 91,53 7,75 92,25 
59.52 34,71 65,29 32,37 67,63 59.52 9,77 90,23 9,98 90,02 
Control 99,59 0,41 99,29 0,71 Control 99,59 0,41 99,29 0,71 
aRBCs (3 days of seniority) were treated for 24 hours with 56 or 57 in PBS. Incubation in an atmosphere of 
20% O2 or 1% O2 (Condition of P. Falciparum Growth) 
Unfortunately, the addition of N-acetyl Cysteine (NAC) to RBCs was not 
protective against the formation of methaemoglobin. 
 
 
Table 5.10. Hemolysis of P. falciparum infected and uninfected RBC, in the presence 
of different concentrations of 56 and 57. 
 ODa 405nm ODa 405 nm 
 RBC W2 
Conc. µM 56 57 56 57 
0.93  0.096 0.098 0.135 0.135 
1.86  0.098 0.099 0.135 0.135 
3.72 0.098 0.101 0.136 0.134 
7.44 0.099 0.105 0.137 0.137 
14.88 0.100 0.108 0.139 0.137 
29.76 0.100 0.113 0.139 0.141 
59.52 0.103 0.117 0.141 0.145 
Control 0.091 0.132 
aOD indicates the release of hemoglobin 
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Finally, it was evaluated the activity of 56 and 57 against P. falciparum, W2 
(CQ-R), pretreated with increasing doses of NAC. As shown in Table 5.12, in 
the presence of NAC, an increase of IC50 only on 57 occurred.  
 
 
 
 
 
 
 
 
 
 
 
 
In conclusion, the fact that NAC protects the parasite from the activity of 57, 
suggested that the mechanism of action of 57 is related to oxidative stress 
induced in the presence of the parasite. In addition, both compounds 56 and 57 
seemed to have oxidizing capacities given that induce the formation of 
methemoglobin. However, the formation of methemoglobin did not appear to 
be related to the compounds mechanism of action, since the NAC, which 
inhibits the activity of 57 on the parasite, did not prevent the methemoglobin’s 
formation. 
 
 
 
 
 
 
 
 
 
Table 5.12. Activity against P. falciparum, W2 (CQ-R) strain, 
pretreated with NAC. 
Compound W2 (CQ-R) 
 
- 
IC50 
(µM) 
NAC 0.1 
IC50 (µM) 
NAC 1 
IC50 (µM) 
NAC 10 
IC50 (µM) 
56 NA NA NA NA 
57 0.70 0.70 1.05 1.34 
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5.6. Conclusions 
The whole series of data obtained led to the identification of several 
antimalarial hit candidates, compounds 28, 33, 57, and shed light on the 
mechanism of action of this kind of molecules. Particularly, the new hit 57 
seemed to have oxidizing capacities, suggesting that the key feature of 
antimalarial activity resides ultimately in disturbing the redox homeostasis in 
the parasitized red blood cells. 
Currently, the new derivatives are still subject of computational studies in order 
to clarify even more the mechanism of action and the pharmacological results.  
It is to be noted that the presence of an electron withdrawing group on the 
benzyl group, such as in derivatives 58-61, did not significantly influenced the 
antiplasmodial activity compared to compound 57 denoting that not only 
electronic factors, acting on the stability of the toxic radical species seemingly 
responsible of the antiplasmodial effects, but further events and factors could 
be involved in their mode of action. However, these preliminary data clearly 
point out the thiazinoquinone scaffold as potential new lead structure for 
antimalarial drugs discovery.  
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CHAPTER 6 
 EXPERIMENTAL SECTION 
 
6.1. Phallusia fumigata 
General Experimental Procedures. High-resolution ESI-MS analyses were 
performed on a Thermo LTQ Orbitrap XL mass spectrometer. The spectra 
were recorded by infusion into the ESI source using MeOH as solvent. Optical 
rotations were measured at 589 nm on a Jasco P-2000 polarimeter using a 10-
cm microcell. 1H (700 MHz) and 13C (175 MHz) NMR spectra were recorded 
on an Agilent INOVA spectrometer equipped with a 13C enhanced HCN Cold 
Probe; chemical shifts were referenced to the residual solvent signal 
(CHD2OD: δH = 3.31, δC = 49.0). For an accurate measurement of the coupling 
constants, the one-dimensional 1H NMR spectra were transformed at 64K 
points (digital resolution: 0.09 Hz). Homonuclear 1H connectivities were 
determined by COSY experiment. Through-space 1H connectivities were 
evidenced using a ROESY experiment with a mixing time of 500 ms. Two and 
three bond 1H-13C connectivities were determined by gradient 2D HMBC 
experiments optimized for a 2,3J of 8 Hz. 3JH-H values were extracted from 1D 
1H NMR. Medium-pressure liquid chromatographies (MPLC) were performed 
on a Büchi 861 apparatus with octadecyl-functionalized silica gel (200-400 
mesh) packed column. High performance liquid chromatography (HPLC) 
separations were achieved on a Shimadzu LC-10AT apparatus equipped with a 
Knauer K-2301 refractive index detector. 
 
Collection, Extraction, and Isolation. Specimens of Phallusia fumigata were 
collected in May 2010 in the bay of Pozzuoli (Napoli, Italy). The samples were 
frozen immediately after collection and stored at −20 °C until extraction. A 
reference specimen is deposited at the Department of Pharmacy, University of 
Naples. The fresh thawed animals (402 g of dry weight after extraction) were 
homogenized and extracted twice with methanol and then twice with 
chloroform (4 x 200 mL). The combined extracts were concentrated in vacuo, 
and the resulting aqueous residue was extracted with EtOAc and subsequently 
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with n-BuOH. Separation of the n-BuOH soluble material (3,06 g) was 
achieved by gradient RP-18 silica gel MPLC (H2O → MeOH → CHCl3) to 
yield nine fractions A–I. The fraction eluted with H2O/MeOH 3:7 v/v, (fraction 
D, 98.2 mg) was chromatographed by HPLC on a RP-18 column (polar-RP 5 
m, 250 x 4.60 mm) eluting with H2O/MeOH 35:65 (v/v), yielding a fraction 
mainly composed of 6 (5.6 mg) which has been further purified by HPLC on a 
RP-18 column (Synergy 4 m, 250 x 4.60 mm), eluting with H2O/MeOH 3:7, 
thus affording phallusiasterol C (1.1 mg) as pure compound. 
 
Phallusiasterol C (6): colorless amorphous solid, [α]D25 -4.0 (c 0.1, CH3OH); 
HRESIMS (negative ion mode, CH3OH) m/z 567.2054 ([M-Na]
-, calcd. for 
C26H40NaO8S2
- 567.2057); 1H and 13C NMR (CD3OD) data are reported in 
Table 3.1.  
 
Transactivation Experiments. To investigate the PXR mediated transactivation, 
HepG2 cells were plated in a 24-wells plate, at 5x104cells/well, and transiently 
transfected with 75 ng of pSG5-PXR, 75 ng of pSG5-RXR, 125 ng of pCMV-
β-galactosidase, and with 250 ng of the reporter vector pCYP3A4promoter-
TKLuc, using Fugene HD transfection reagent (Roche). At 24 hours, post-
transfection, cells were primed 18 hours with Rifaximin and 6 (10μM) or with 
the combination of Rifaximin (10μM) plus compound 6 (50 μM). After 
treatments, cells were lysed in 100 μL Lysis Buffer (25 mM TRIS-phosphate 
pH 7.8; 2mM DTT; 10% glycerol; 1% Triton X-100) and 20 μL cellular lysate 
was assayed for Luciferase activity using the Luciferase Assay System 
(Promega). Luminescence was measured using an automated luminometer 
(Glomax 20/20, Promega). Luciferase activities were normalized for 
transfection efficiencies by dividing the Luciferase relative light units (RLU) 
by β- galactosidase activity (βgal) expressed from cells co-transfected with 
pCMVβgal. All experiments were performed in triplicate 
 
Cells culture, RNA extraction and Real-Time PCR. HepG2 cells were cultured 
at 37 °C in E-MEM supplemented with 10% FBS, 1% l-glutamine and 1% 
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penicillin/streptomycin. To evaluate PXR target genes expression, serum 
starved HepG2 cells were stimulated for 18 h with Rifaximin and compound 6 
(10μM). Total RNA was extracted using the TRIzol reagent (Invitrogen), 
purified of the genomic DNA by DNAase I treatment (Invitrogen) and random 
reverse-transcribed with Superscript II (Invitrogen). 10 ng template was 
amplified using the following reagents: 0.2 μM of each primer and 10μl of 
KAPA SYBR FAST Universal qPCR Kit (KAPA BIOSYSTEMS). All 
reactions were performed in triplicate and the thermal cycling conditions were: 
3 min at 95 °C, followed by 40 cycles of 95 °C for 15 s, 58 °C for 20 s and 72 
°C for 30 s. The relative mRNA expression was calculated and expressed as 
2−(ΔΔCt). Primers used for qRT-PCR were: hGAPDH: 
GAAGGTGAAGGTCGGAGT and CATGGGTGGAATCATATTGGAA; 
hCYP3A4: CAAGACCCCTTTGTGGAAAA and 
CGAGGCGACTTTCTTTCATC; hMDR1: GTGGGGCAAGTCAGTTCATT 
and CTTCACCTCCAGGCTCAGT. 
 
Statistical Analysis. All values are expressed as means ± standard error (SE) of 
n observations/group. Comparisons of two groups were made with a one-
wayANOVA with post hoc Tukey’s test. Differences were considered 
statistically significant at values of P < 0.05. 
 
6.2. Electrochemical and computational studies 
Reagents, compound isolation and characterization. Double stranded 
deoxyribonucleic acid sodium salt from salmon testes (dsDNA) was purchased 
from Sigma and used as received. Compounds 12-15 (Figure 3.4) were 
isolated and characterized as previously reported. 
 
Electrochemical studies. Electrochemical experiments were performed at 
298±1 K in a thermostated cell with CH I660 equipment. A BAS MF2012 glassy 
carbon working electrode (GCE) (geometrical area 0.071 cm2), a platinum wire 
auxiliary electrode and an Ag/AgCl (3M NaCl) reference electrode were used in a 
typical three-electrode arrangement. 0.10 M Phosphate buffer saline (PBS) at pH 
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7.4 (from Merck reagents) was used for experiments in aqueous solution. 
Experiments in DMSO (Carlo Erba) were performed using 0.10 M Bu4NPF6 
(Fluka) as a supporting electrolyte. Prior to electrochemical runs, all solutions 
were deaerated by bubbling Ar during 15 min. 
The electrochemistry of films of the studied receptors on glassy carbon electrode 
was studied using the methodology previously described by pipeting 10 L of a 
solution (1 mg/mL), previously ultrasonicated by 5 min, of the compound in 
ethanol and allowing the solvent to evaporate in air. As a result, a uniform, fine 
coating of the quinones was adhered to the basal electrode. 
 
Computational studies. Apparent pKa values were calculated by using 
ACD/Percepta software.130 The compounds were built, taking into account the 
prevalent ionic forms at physiological pH (7.4), using the Insight 2005 Builder 
module (Accelrys Software Inc., San Diego). Atomic potentials and charges 
were assigned using the CFF91 force field.131 The conformational space of the 
compounds was sampled through 200 cycles of Simulated Annealing (ε = 
80*r). The following protocol was applied: the system was heated up to 1000 
K over 2000 fs (time step = 3.0 fs); the temperature of 1000 K was applied to 
the system for 2000 fs (time step = 3.0 fs) with the aim of surmounting 
torsional barriers; successively, temperature was linearly reduced to 300 K in 
1000 fs (time step = 1.0 fs). Resulting conformations were then subjected to 
molecular mechanic (MM) energy minimization within Insight 2005 Discover 
module (CFF91 force field; ε = 80*r) until the maximum RMS derivative was 
less than 0.001 kcal/Å, using Conjugate Gradient132 as minimization algorithm. 
MM conformers were then subjected to a full geometry optimization by semi-
empirical calculations, using the quantum mechanical method PM7133 in the 
                                                          
130ACD/Percepta, Advanced Chemistry Development, Inc., Toronto, ON, Canada, 2015, 
http://www.acdlabs.com.  
131 Maple, J.R.; Hwang, M.J.; Stockfisch, T.P.; Dinur, U.; Waldman, M.; Ewig, C.S.; Hagler, 
A.T. J. Comput. Chem. 1994, 15, 162−182. 
132 Fletcher, R.; Unconstrained Optimization. In Practical Methods of Optimization; John 
Wiley & Sons: New York, 1980, vol. 1. 
 
133 Stewart, J.J. J. Mol. Model. 2013, 19, 1–32. 
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Mopac2012 package134 and EF (Eigenvector Following routine)135 as geometry 
optimization algorithm. GNORM value was set to 0.01. To reach a full 
geometry optimization, the criteria for terminating all optimizations were 
increased by a factor of 100, using the keyword PRECISE. Resulting 
conformers were ranked by their potential energy values (i.e., ΔE from the 
global energy minimum) and grouped into conformational families. The 
occurrence rates and ΔEGM range for each conformational family were 
calculated. The lowest energy minima of each family have been then subjected 
to DFT calculations. All structures were fully optimized in gas-phase and 
characterized as minima at the B3LYP/6-31+G (d, p) level.136 The calculations 
were carried out using the Gaussian 09 package.137 
Starting from the structure of the Q (i.e., the starting quinone species) GM 
conformers, the redox states Q•-, QH•i, QH
•
ii, QHi
-, QHii
-, QH2 were generated. 
In particular, following the reduction pathway of quinones reported in Scheme 
3.1, each species was generated starting from the DFT optimized species of the 
previous step. The reaction energies (kcal/mol) for the electron/proton transfer 
of each step of the reduction reaction E(QQ.-) were calculated: In particular, 
gas phase reaction energy calculations for electron attachment were 
accomplished by determining ΔE of the reaction Y + e-→ Y- that is, ΔE = E(Y-) 
- E(Y), where Y is the Q or QH• DFT conformer. Reaction energies for proton 
                                                          
134 MOPAC2012; Stewart Computational Chemistry: Colorado Springs, CO, USA; 
http://OpenMOPAC.net (2012) 
135 Baker, J. J. Comput. Chem. 1986, 7, 385−395. 
136 a) Becke, A. D. J. Chem. Phys. 1993, 98, 5648−5652; (b) Lee, C.; Yang, W.; Parr, R. G. 
Phys. Rev. B: Condens. Matter Mater. Phys. 1988, 37, 785−789.  
137 Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; 
Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A.; Nakatsuji, H.; Caricato, M.; Li, X.; 
Hratchian, H.P.; Izmaylov, A.F.; Bloino, J.; Zheng, G.; Sonnenberg, J.L.; Hada, M.; Ehara, M.; 
Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, 
H.; Vreven, T.; Montgomery, J.A.Jr.; Peralta, J.E.; Ogliaro, F.; Bearpark, M.; Heyd, J.J.; 
Brothers, E.; Kudin, K.N.; Staroverov, V.N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; 
Rendell, A.; Burant, J.C.; Iyengar, S.S.; Tomasi, J.; Cossi, M.; Rega, N. ; Millam, N.J.;. Klene, 
M.; Knox, J.E.; Cross, J.B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, 
R.E.; Yazyev, O.; Austin, A.J.; Cammi, R.; Pomelli, C.; Chterski, J.W.; Martin, R.L.; 
Morokuma, K.; Zakrzewski, V.G.; Voth, G.A.; Salvador, P.; Dannenberg, J.J.; Dapprich, S.; 
Daniels, A.D.; Farkas, O.; Foresman, J.B.; Ortiz, J.V.; Cioslowski, J.; Fox, D.J. Gaussian 09, 
revision A.1. Gaussian Inc. Wallingford, 2009. 
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attachment were calculated by determining ΔE of the reaction Y + H+ → YH 
that is ΔE = E(YH) - E(Y), where Y is Q•- or QH- DFT conformer.138 
For each considered redox state, the energy of the frontier molecular orbitals 
(HOMO, LUMO, and SOMO) were used to calculate the following parameters: 
i) the electrophilicity index (ω), ii) the vertical ionization potential (IP), iii) the 
vertical electron affinity (EA). The electrophilicity indexes (ω) were calculated 
following the expression ω = (μ2/2η), where μ is the chemical potential given 
by μ = - (IP + EA)/2 and η is the chemical hardness given by η = (IP - EA), 
where IP = E(N=N0-1) - E(N=N0) and EA = E(N=N0) - E(N=N0+1). Here, N0 is 
the number of electrons in the ground state of the (usually neutral) system. 
Thus, the single point energies (E) of the cationic (N0-1 electron system), and 
anionic (N0+1 electron system) forms for each considered species were 
calculated for each compound. 
 
6.3. Synthesis of phosphoeleganin’s analogues 
General Experimental Procedures. Optical rotations were measured at 589 nm 
with a Jasco P-2000 polarimeter using a 10-cm microcell. HRMS (ESI positive 
mode) was performed with a Thermo LTQ Orbitrap XL mass spectrometer. 
The spectra were recorded by infusion into the ESI source using MeOH as 
solvent. CD spectra were recorded with a J-710 spectropolarimeter (Jasco, 
Tokyo, Japan) with J-710 for Windows software (Jasco). 1H (700 MHz) and 
13C (175 MHz) NMR spectra were recorded on an Agilent INOVA 
spectrometer; chemical shifts were referenced to the residual solvent signal 
(CD3OD: δH = 3.31, δC = 49.0; CDCl3: δH = 7.26, δC = 77.0). Homonuclear 1H 
connectivities were determined by COSY experiments. Two and three bond 
1H-13C connectivities were determined by gradient 2D HMBC experiments 
optimized for a 2,3J of 8 Hz. Medium-pressure liquid chromatographies 
(MPLC) were performed on a Büchi 861 apparatus with octadecyl-
functionalized silica gel (200-400 mesh) packed column. High performance 
                                                          
138 Sawyer, A.; Sullivan, E.; Mariam, Y.H. J. Comput. Chem. 1996, 17, 204-225. 
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liquid chromatography (HPLC) separation was achieved on a Knauer K-501 
apparatus equipped with an Knauer K-2301 RI detector. 
 
Collection, Extraction, and Isolation. Compound 16 (Figure 4.1) was isolated 
and characterized as previously reported. 
 
Synthesis of compound 18. Compound 18 was prepared from a solution of cis-
4-decenal (424 mg, 2,75 mmol, 1.0 equiv) in anhydrous THF (20mL) to which 
was added n-BuLi dropwise (2.06 mL, 1.6 M in hexane, 3.30 mmol, 1.2 equiv). 
The reaction mixture was stirred at -78°C for 10 min and after for an additional 
8h at rt. The reaction was quenched with saturated NH4Cl and extracted with 
EtOAc. The organic phase was dried over anhydrous Na2SO4 and solvent 
removed with rotary evaporation. (18): 1H-NMR (700 MHz, CDCl3)  0.84 (m, 
6H), 1.20-1.51 (m, 14H), 1.95 (m, 2H), 2.05 (m, 1H), 2.12 (m, 1H), 3.54 (m, 
1H), 5.32 (m, 2H). 13C-NMR (175 MHz, CDCl3)  14.0, 22.5, 22.7, 23.4, 27.1, 
27.7, 29.3, 31.4, 37.0, 37.1, 71.5, 129.1, 130.5. ESI-MS (pos.) m/z 213.22 
[M+H] +. 
 
Synthesis of compounds 19* and 20*. 495 mg of compound 18 (2.3 mmol, 1 
equiv) were dissolved with acetone/H2O (9:1, 10 mL), added NMO (410 mg, 
3.5 mmol, 1.5 equiv) and OsO4 (1 mol%, 6mg). The reaction mixture was 
stirred overnight at rt. The reaction was quenched with saturated Na2SO3 
solution and extracted with EtOAc (3x). Organic layer was dried over anydrous 
Na2SO4, filtered and concentrated in vacuo. Separation by reverse phase HPLC 
(Luna C18 10 MeOH/H2O 7:3) of the obtained stereisomeric triols mixture 
gave two diastereoisomeric fractions, rac-19 (55.1 mg, tr 12.6 min) and rac-20 
(61.4 mg, tr 14.4 min), as enatiomeric mixtures. ESI-MS (pos.) m/z 247.22 
[M+H] +. 
 
Synthesis of compounds 21-22 and 23-24. Esterification reaction was carried 
out both on fraction rac-19 (5.1 mg, 0.048 mmol) that rac-20 (18.1 mg, 0.074 
mmol) respectively each dissolved in CH2Cl2 dry (3mL). To a rac-19 
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compound solution was added EDC (37.4 mg, 0.195 mmol), DMAP (11.8 mg, 
0.096 mmol) and (R)-methoxyphenylacetic acid (6.32 mg, 0.195 mmol). 
Instead, to a rac-20 compound solution was added EDC (63.3 mg, 0.334 
mmol), DMAP (18.1 mg, 0.148 mmol), (R)-methoxyphenylacetic acid (54.8 
mg, 0.334 mmol). Each mixture was stirred overnight under N2 atmosphere at 
rt. After solvent evaporation, HPLC purification of two mixtures on SiO2 
column (Luna SiO2 3µ), eluiting with Hexane/ EtOAc 85:15 (v/v), each gave 
two diastereoisomeric triesters 21 (2.1 mg, tr 3.74 min), 22 (2.3, tr 4.64 min), 
23 (7.8 mg, tr 3.12 min) and 24 (8.0 mg, tr 4.32 min).  
(21): 1H NMR (700 MHz, CDCl3, J in Hz) 0.67 (t, 7.6, 3H, H-1), 0.98 
(overlapped, 2H, H-2), 0.61 (m, 2H, H-3), 0.94 (overlapped, 1H, H-4a), 0.98 
(overlapped,1H, H-4b), 4.42 (m, 1H, H-5), 0.56 (m, 1H, H-6a), 0.88 
(overlapped, 1H, H-6b), 0.93 (overlapped, 1H, H-7a), 1.14 (m, 1H, H-7b), 4.66 
(m, 1H, H-8), 5.09 (m, 1H, H-9), 1.36 (overlapped, 1H, H-10a), 1.39 
(overlapped, 1H, H-10b), 1.22 (overlapped, 2H, H-11), 1.22 (overlapped, 2H, 
H-12), 1.25 (overlapped, 2H, H-13), 0.86 (t, 7.6, 3H, H-14); 13C NMR (CDCl3, 
signals assigned from HSQC data) 13.5 (C-1), 22.1 (C-2), 26.2 (C-3), 33.4 
(C-4), 74.9 (C-5), 29.1 (C-6), 24.0 (C-7), 74.7 (C-8), 74.1 (C-9), 29.9 (C-10), 
24.9 (C-11), 31.1 (C-12), 22.3 (C-13), 13.7 (C-14). HRMS (ESI): m/z [M +Na] 
+ calcd. for C41H54O9Na
+: 713.3660, found: 713.3680. 
(22): 1H NMR (700 MHz, CDCl3, J in Hz) 0.84 (t, 7.6, 3H, H-1), 1.25 
(overlapped, 2H, H-2), 1.16 (overlapped, 2H, H-3), 1.39 (m, 1H, H-4a), 1.48 
(m,1H, H-4b), 4.80 (m, 1H, H-5), 1.31 (overlapped, 2H, H-6), 0.80 
(overlapped, 1H, H-7a), 1.02 (m, 1H, H-7b), 4.88 (m, 1H, H-8), 4.40 (m, 1H, 
H-9), 0.79 (overlapped, 1H, H-10a), 0.84 (overlapped, 1H, H-10b), 0.46 (m, 
1H, H-11a), 0.52 (m, 1H, H-11b) 1.31 (overlapped, 2H, H-12), 0.91 (m, 2H, H-
13), 0.68 (t, 7.6, 3H, H-14); 13C NMR (CDCl3, signals assigned from HSQC 
data) 13.8 (C-1), 22.3 (C-2), 27.1 (C-3), 33.9 (C-4), 74.7 (C-5), 30.4 (C-6), 
25.5 (C-7), 74.4 (C-8), 74.7 (C-9), 26.9 (C-10), 23.9 (C-11), 30.3 (C-12), 22.1 
(C-13), 13.5 (C-14). HRMS (ESI): m/z [M +Na] + calcd. for C41H54O9Na
+: 
713.3660, found: 713.3677. 
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(23): 1H NMR (700 MHz, CDCl3, J in Hz) 0.68 (t, 7.6, 3H, H-1), 1.05 (m, 
2H, H-2), 0.83 (overlapped, 2H, H-3), 1.29 (overlapped, 1H, H-4a), 1.31 
(overlapped,1H, H-4b), 4.83 (m, 1H, H-5), 1.42 (overlapped, H, H-6a), 1.46 
(overlapped, 1H, H-6b), 1.37 (overlapped, 1H, H-7a), 1.44 (overlapped, 1H, H-
7b), 5.07 (m, 1H, H-8), 4.69 (m, 1H, H-9), 0.99 (overlapped, 2H, H-10), 0.54 
(overlapped, 1H, H-11a), 0.59 (overlapped, 1H, H-11b), 0.74 (m, 1H, H-12a), 
0.82 (overlapped, 1H, H-12b), 0.91 (m, 2H, H-13), 0.67 (t, 7.6, 3H, H-14); 13C 
NMR (CDCl3, signals assigned from HSQC data) 13.7 (C-1), 22.1 (C-2), 
26.7 (C-3), 33.4 (C-4), 74.2 (C-5), 29.9 (C-6), 25.9 (C-7), 74.5 (C-8), 74.8 (C-
9), 27.6 (C-10), 23.9 (C-11), 30.9 (C-12), 22.1 (C-13), 13.7 (C-14). HRMS 
(ESI): m/z [M +Na] + calcd. for C41H54O9Na
+: 713.3660, found: 713.3681. 
 (24): 1H NMR (700 MHz, CDCl3, J in Hz) 0.81 (t, 7.6, 3H, H-1), 1.16 
(overlapped, 2H, H-2), 0.93 (overlapped, 2H, H-3), 0.99 (overlapped, 1H, H-
4a), 1.21 (overlapped,1H, H-4b), 4.53 (m, 1H, H-5), 0.74 (overlapped, 2H, H-
6), 0.77 (overlapped, 1H, H-7a), 0.89 (overlapped, 1H, H-7b), 4.61 (m, 1H, H-
8), 5.00 (m, 1H, H-9), 1.16 (overlapped, 1H, H-10a), 1.22 (overlapped, 1H, H-
10b), 1.16 (overlapped, 2H, H-11), 1.22 (overlapped, 2H, H-12), 1.24 
(overlapped, 2H, H-13), 0.85 (t, 7.6, 3H, H-14); 13C NMR (CDCl3, signals 
assigned from HSQC data) 13.8 (C-1), 22.4 (C-2), 27.1 (C-3), 33.4 (C-4), 
73.9 (C-5), 28.8 (C-6), 22.6 (C-7), 74.2 (C-8), 74.4 (C-9), 29.6 (C-10), 24.9 (C-
11), 31.4 (C-12), 22.4 (C-13), 13.9 (C-14). HRMS (ESI): m/z [M +Na] + calcd. 
for C41H54O9Na
+: 713.3660, found: 713.3688. 
 
Synthesis of compound 19. Pure enantiomeric 19 triol was obtained by 21 (2 
mg, 0.003 mmol) compound’s hydrolysis reaction with NaOH (400 mg, 10 
mmol) in MeOH (3mL) and any water drops. The mixture was stirred at rt 
overnight, then diluted with HCl (1% solution), washed with brine and the triol 
was extracted with 20 mL BuOH (3x). The organic extract was dried over 
anhydrous Na2SO4 and then concentrated in vacuo. Reverse phase HPLC 
(Luna 5µ C18), eluiting with MeOH: H2O 7:3, allowed triol purification (2mg, 
tr 10.5 min). (19): 1H NMR (700 MHz, CD3OD, J in Hz), view H and C (rac-
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19) in Table 4.1. ESI-MS (pos.) m/z 247.22 [M+H] + [D25: +3.71 (0.009, 
MeOH). 
 
Synthesis of compound 20. 20 triol (3.6mg, tr 12.0 min) was obtained by the 
same reaction and purification (reverse phase HPLC MeOH: H2O 7:3) of 19 
reported above, using 4,8 mg (0.007 mmol) of 23. (20): 1H NMR (700 MHz, 
CD3OD, J in Hz), view H and C (rac-20) in Table 4.1. ESI-MS (pos.) m/z 
247.22 [M+H] +. [D25: +1.56 (0.015, MeOH). 
 
Cyclization of 19* enantiomeric mixture. 10.4 mg of rac-19 (0.0422 mmol, 1.0 
equiv) were dissolved in CH2Cl2 (5 mL) and added trimethyl orthoacetate (7 
µL, 1.2 equiv), PPTS (0.100 mg, 0.01 equiv) at rt. Spent 15 min, BF3•Et2O 
(0.53 µL, 0.1 equiv) was added at 0°C and when TLC showed orthoester 
absence, the mixture was quenched with H2O/Acetone 9:1 and after solvent 
was removed in vacuo. Cyclised product 25 was obtained quantitatively. (25): 
1H NMR (700 MHz, CD3OD, J in Hz), view H and C in Table 4.2. HRMS 
(ESI): m/z [M +Na] + calcd. for C16H30O3Na
+: 293.2087, found: 293.2075. 
 
Cyclization of 20* enantiomeric mixture: Using 10.5 mg of rac-20 (0.0422 
mmol, 1.0 equiv), compound 26 was obtained with the same conditions of 25 
reported above. (26): 1H NMR (700 MHz, CD3OD, J in Hz), view H and C in 
Table 4.2. HRMS (ESI): m/z [M +Na] + calcd. for C16H30O3Na
+: 293.2087, 
found: 293.2083. 
 
 6.4. Synthesis of thiazinoquinone derivatives 
General experimental procedures. High-resolution ESI-MS analyses were 
performed on a Thermo LTQ Orbitrap XL mass spectrometer (Thermo-Fisher, 
San Josè, CA, USA). The spectra were recorded by infusion into the ESI 
(Thermo-Fisher, San Josè, CA, USA) source dissolving the sample in MeOH. 
1H (700 MHz) and 13C (175 MHz) NMR spectra were recorded on an Agilent 
INOVA spectrometer (Agilent Technology, Cernusco sul Naviglio, Italy) 
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equipped with a 13C enhanced HCN Cold Probe; chemical shifts were 
referenced to the residual solvent signal (CDCl3: δH = 7.26, δC = 77.0; DMSO-
d6 δH = 2.39, δC = 39.0). For an accurate measurement of the coupling 
constants, the one-dimensional 1H NMR spectra were transformed at 64 K 
points (digital resolution: 0.09 Hz). Homonuclear (1H- 1H) and heteronuclear 
(1H-13C) connectivities were determined by COSY and HSQC experiments, 
respectively. Two and three bond 1H-13C connectivities were determined by 
gradient 2D HMBC experiments optimized for a 2,3J of 8 Hz. 3JH-H values were 
extracted from 1D 1H NMR. High performance liquid chromatography (HPLC) 
separations were achieved on a Shimadzu LC-10AT (Shimadzu, Milan, Italy) 
apparatus equipped with a Knauer K-2301 (LabService Analytica s.r.l., Anzola 
dell'Emilia, Italy) refractive index detector. 
 
Reagents. Sigma–Aldrich. Solvents: Carlo Erba. TLC: Silica Gel 60 F254 
(plates 5 x 20, 0.25 mm) Merck. Preparative TLC: Silica Gel 60 F254 plates 
(20 x 20, 2 mm). Spots revealed by UV lamp then by spraying with 2 N 
sulfuric acid and heating at 120 °C. Anhydrous solvents: Sigma–Aldrich or 
prepared by distillation according to standard procedures 
 
Synthesis of compounds 39-42. Aqueous sodium hydroxide (1 M; 1 mL) was 
added to a solution of 0.055 mmol of each starting compound (15 mg of 28, 
19.5 mg of 30, 18.7 mg of 33 and 34) dissolved in 2 mL of methanol. The 
mixture was stirred for 3 hours at room temperature. Subsequently, the reaction 
mixture was diluted with hydrochloric acid (2 M; 5 mL); then extracted with 
ethyl acetate three times. The combined organic phases were dried over MgSO4 
and the solvent was evaporated. The residue was purified by column 
chromatography on silica gel (EtOAc/hexane 6:4) to afford the pure 
compounds 39 (6 mg, 28%), 41 (6.0 mg, 32%), 42 (5.8 mg, 31%) and only the 
only compound 40 (4 mg, 28%) as collateral product. NMR data of compounds 
39, 40, 42 (CD3OD) and 41 (DMSO-d6) are reported in Tables 5.1 and 5.2. 
(39): ESI MS (positive ions): m/z 337 ([M-H] -). (40): ESI MS (positive ions): 
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m/z 278 ([M+Na] +). (41) ESI MS (positive ions): m/z 376 ([M+Na] +). (42): 
ESI MS (positive ions): m/z 337 ([M-H] -). 
 
Synthesis of compounds 44-R1, 44-R2 and 44-R3. 1.68 g (10 mmol) of 1,2,4-
trimethoxybenzene (43) were dissolved in 25 mL of anhydrous THF and 12.5 
mL of a n-BuLi 1.6 M solution (20 mmol) were added, under argon 
atmosphere at rt; the mixture was stirred for 1 h. Then, the bromoalkane (20 
mmol; 2.2 mL of 1-bromo-2-methylpropane, 2.1 mL of 1-bromobutane and 2.8 
mL of (bromomethyl)cyclohexane) were added and the mixture was left under 
stirring for 24 h (the end of the reaction was controlled with TLC, eluent: 
chloroform/hexane 7:3). After this time, the mixture was poured into cold 
water (150 mL) and extracted three times with ether. The ethereal solution was 
washed with brine several times ,dried over sodium sulfate, filtered and 
concentrated. The residue was purified by column chromatography on silica 
gel (hexane/EtOAc 9:1) to afford 44-R1 (1.8 g, 80.3% yield) , 44-R2 (1.7 g, 
76.0% yield)  and 44-R3 (2.0g, 76.5% yield)  as colorless oil.  
44-R1: 1H-NMR (CDCl3): 6.68 (
1H, d, J = 8.8 Hz, H-6); 6.51 (1H, d, J = 8.8 
Hz, H-5); 3.79 (3H, s, -OCH3); 3.78 (3H, s, -OCH3); 3.73 (3H, s, -OCH3); 2.49 
(2H, d, J = 7.3 Hz, CH2); 1.89 (1H, m, J = 7.3 Hz-6.7 Hz, CH); 0.86 (6H, d, J = 
6.7Hz, CH3). HRMS (ESI): m/z [M +Na]
+ calcd. for C13H20O3Na
+: 247.1305, 
found: 247.1314.  
44-R2: 247.1315; 1H-NMR (CDCl3): 6.69 (
1H, d, J = 8.8 Hz, H-6); 6.52 (1H, d, 
J = 8.8 Hz, H-5); 3.77 (3H, s, -OCH3); 3.74 (3H, s, -OCH3); 3.72 (3H, s, -
OCH3); 2.63 (2H, t, J = 7.4 Hz, CH2CH2CH2CH3); 1.49 (2H, m, 
CH2CH2CH2CH3); 1.38 (2H, m, CH2CH2CH2CH3 ); 0.92 (3H, d, J = 6.7Hz, 
CH3). HRMS (ESI): m/z [M +Na]
+ calcd. for C13H20O3Na
+: 247.1305, found:  
44-R3: 1H-NMR (CDCl3): 6.69 (
1H, d, J = 8.8 Hz, H-6); 6.52 (1H, d, J = 8.8 
Hz, H-5); 3.80 (3H, s, -OCH3); 3.78 (3H, s, -OCH3); 3.74 (3H, s, -OCH3); 2.50 
(2H, d, J = 7.4 Hz, CH2-cyclohexyl); 1.55 (1H, m, CH); 1.53-0.95 (4H, m); 
1.15-1.66 (4H, m), 1.60(2H, m). HRMS (ESI): m/z [M +Na]+ calcd. for 
C16H24O3Na
+: 287.1618, found: 287.1626. 
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Synthesis of compounds 45-R1, 45-R2 and 45-R3. 3.5 mmol of each compound 
(680 mg of 44-R1, 680 mg of 44-R2, 820 mg of 44-R3) dissolved in 90 mL of 
acetonitrile were added dropwise to a solution of CAN (9.6 g, 17.5 mmol) in 
water (100mL) at 0°C. The mixture was stirred for 30 minutes at room 
temperature (the end of the reaction was checked by TLC, eluent: chloroform/ 
EtOAc 7:3). The orange liquid was then poured into 100 mL of cold water and 
extracted three times with ether. The combined organic layers were washed 
with brine, dried over sodium sulfate, and filtered. The solvent removal under 
reduced pressure afforded 45-R1 (382 mg, 65%), 45-R2 (382 mg, 65%) and 45-
R3 (540 mg, 74 %) sufficiently pure for the following reaction.  
(45-R1): 1H-NMR (CDCl3): 6.66 (
1H, d, J = 10.0 Hz, H-6); 6.51 (1H, d, J = 
10.0 Hz, H-5); 3.99 (3H, s, -OCH3); 2.34 (2H, d, J = 7.3 Hz, CH2); 1.81 (1H, 
m, J = 7.3 Hz-6.7 Hz, CH); 0.89 (6H, d, J = 6.7Hz, CH3). HRMS (ESI): m/z 
[M +Na]+ calcd. for C11H14O3Na
+: 217.0835, found: 217.0841; 
(45-R2): 1H-NMR (CDCl3): 6.66 (
1H, d, J = 10.0 Hz, H-6); 6.51 (1H, d, J = 
10.0 Hz, H-5); 4.01 (3H, s, -OCH3); 2.42 (2H, t, J = 7.4 Hz, CH2CH2CH2CH3); 
1.47 (2H, m, CH2CH2CH2CH3); 1.39 (2H, m, CH2CH2CH2CH3 ); 0.92 (3H, d, J 
= 6.7Hz, CH3). HRMS (ESI): m/z [M +Na
+]+ calcd. for C11H14O3Na
+: 
217.0835, found: 217.0843. 
(45-R3): 1H-NMR (CDCl3): 6.69 (
1H, d, J = 8.8 Hz, H-6); 6.52 (1H, d, J = 8.8 
Hz, H-5); 4.01 (3H, s, -OCH3); 2.35 (2H, d, J = 7.4 Hz, CH2-cyclohexyl); 1.55 
(1H, m, CH); 1.53-0.95 (4H, m); 1.15-1.66 (4H, m), 1.60 (2H, m). HRMS 
(ESI): m/z [M +Na+]+ calcd. for C14H18O3Na
+: 257.1148, found: 257.1139. 
 
Synthesis of compounds 46-51. 1.5 mmol of each quinone (290 mg of 45-R1, 
290 mg of 45-R2, 350 mg of 45-R3) were dissolved in a mixture of 
EtOH/CH3CN 1:1 and heated in a water bath under stirring; then, a solution of 
hypotaurine (163.7 mg, 1.5 mmol) in 8 mL of water and a catalytic amount of 
salcomine were added in portions. The mixture was stirred for 24 h at room 
temperature and the yellow solution became orange/red. Most of the ethanol 
was removed in vacuo and the residue was poured into water. The mixture was 
extracted with ether (three times) and the organic phase was washed with brine, 
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dried over sodium sulfate, and filtered. Solvent removal gave residues 
containing mixtures of compounds 46/47 (from 45-R1, 170 mg, 38 % yield), 
48/49 (from 45-R2, 173 mg, 39 % yield) as well as of compounds 50/51 (from 
45-R3, 167 mg, 33 % yield); they were separated as reported below. 
 
Separation of crude mixtures of 46/47, 48/49 and 50/51 isomers. Separation of 
isomers 46/47 mixture (170 mg) was achieved by HPLC on a SiO2 column 
(Luna 5µm, 250 x 4.60 mm) eluting with EtOAc/hexane 6:4 (v/v) and afforded 
pure compounds 46 (16 mg) and 47 (62 mg). Mixture of isomers 48/49 (170 
mg), as well as that of 50/51 (167 mg), were separated in the same conditions 
and yielded pure compounds 48 (14 mg), 49 (60 mg), 50 (11 mg), and 51 (43 
mg). 
(46): HPLC EtOAc/hexane 6:4 (v/v), (tR): 13.5 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.3. HRMS (ESI): m/z [M +Na] + calcd. for 
C13H17NO5SNa
+: 322.0720, found: 322.0727. 
(47): HPLC EtOAc/hexane 6:4 (v/v), (tR): 24 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.3. HRMS (ESI): m/z [M +Na] + calcd. for 
C13H17NO5SNa
+: 322.0720, found: 322.0729. 
(48): HPLC EtOAc/hexane 6:4 (v/v), (tR): 11.5 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.3. HRMS (ESI): m/z [M +Na] + calcd. for 
C13H17NO5SNa
+: 322.0720, found: 322.0733. 
(49): HPLC EtOAc/hexane 6:4 (v/v), (tR): 22 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.3. HRMS (ESI): m/z [M +Na] + calcd. for 
C13H17NO5SNa
+: 322.0720, found: 322.0735. 
(50): HPLC EtOAc/hexane 6:4 (v/v), (tR): 11.8 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.4. HRMS (ESI): m/z [M +Na] + calcd. for 
C16H21NO5SNa
+: 362.1033, found: 362.1042. 
(51): HPLC EtOAc/hexane 6:4 (v/v), (tR): 21.4 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.4. HRMS (ESI): m/z [M +Na] + calcd. for 
C16H21NO5SNa
+: 362.1033, found: 362.1038. 
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Synthesis of compounds 53-R4, 53-R5 and 53-R6. To a solution of 1,2,4-
trimethoxybenzene (52, 1.0 mL, 6.7 mmol) in THF (25 mL) was added 6 mL 
n-BuLi 1.6 M solution (10 mmol) under argon atmosphere at 0 °C; the mixture 
was stirred for 1 h. Then, the aldehyde (10 mmol; 1.0 mL of benzaldehyde, 1.4 
g of 4-chlorobenzaldehyde, 1.3 mL of 4-(trifluoromethyl)benzaldehyde were 
added and the mixture was left under stirring at room temperature overnight. 
and quenched by adding saturated aqueous NH4Cl (30 mL). The two layers 
were separated and the aqueous layer was extracted with ether (three times). 
The combined organic layers were washed with brine, dried over anhydrous 
sodium sulfate, and concentrated. The crude material was purified by column 
chromatography on silica gel (hexane/EtOAc 8:2) to afford the corresponding 
secondary benzylic alcohols 53-R4 (1.3 g, 70% yield), 53-R5 (1.5 g, 73% 
yield), 53-R6 (1.6 g, 70% yield): (1.3 g, 70% yield). 
(53-R4) 1H-NMR (CDCl3): 6.82 (1H, d, J = 8.8 Hz, H-6); 6.62 (1H, d, J = 8.8 
Hz, H-5); 3.82 (3H, s, -OCH3); 3.74 (3H, s, -OCH3); 3.61 (3H, s, -OCH3); 6.25 
(1H, d, J = 11.7 Hz, CH-OH); 7.36 (2H, d, J = 7.0 Hz); 7.28 (2H, t, J = 7.6Hz); 
7.19 (1H, t, J = 7.6Hz); 4.29 (1H, d, J = 11.7Hz, OH). HRMS (ESI): m/z [M 
+Na.] + calcd. for C16H18O4Na
+: 297.1097, found: 297.1109. 
(53-R5) 1H-NMR (CDCl3): 6.82 (1H, d, J = 8.8 Hz, H-6); 6.62 (1H, d, J = 8.8 
Hz, H-5); 3.81 (3H, s, -OCH3); 3.72 (3H, s, -OCH3); 3.62 (3H, s, -OCH3); 6.24 
(1H, d, J = 11.7 Hz, CH-OH); 7.23 (2H, d, J = 8.3 Hz); 7.27 (2H, d, J = 
8.3Hz); 4.29 (1H, d, J = 11.7Hz, OH). HRMS (ESI): m/z [M +Na] + calcd. for 
C16H17ClO4Na
+: 331.0708, found: 331.0719. 
(53-R6) 1H-NMR (CDCl3): 6.82 (1H, d, J = 8.8 Hz, H-6); 6.62 (1H, d, J = 8.8 
Hz, H-5); 3.78 (3H, s, -OCH3); 3.68 (3H, s, -OCH3); 3.63 (3H, s, -OCH3); 6.30 
(1H, brs, CH-OH); 7.53 (2H, d, J = 8.3 Hz); 7.50 (2H, d, J = 8.3Hz); 4.29 (1H, 
brs, OH). HRMS (ESI): m/z [M +Na] + calcd. for C17H17F3O4Na
+: 365.10971, 
found: 365.0954. 
 
Synthesis of compounds 54-R4, 54-R5 and 54-R6. Trifluoracetic acid (0.5 mL, 
7,1 mmol) was slowly added to a solution of each compound (2.4 mmol; 650 
mg of 53-R4, 740 mg of 53-R5, 821 mg of 53-R6) and triethylsilane (1.1 mL, 
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7.1 mmol) in dichloromethane (30 mL). The mixture was stirred at room 
temperature overnight. The organic phase was washed with a sodium carbonate 
solution (30 mL) and dried. The solvent removal afforded 54-R4 (570 mg, 
93%) 54-R5 (661 mg, 94%), 54-R6 (720 mg, 92%) sufficiently pure for the 
following reaction.  
(54-R4) 1H-NMR (CDCl3): 6.73 (1H, d, J = 8.8 Hz, H-6); 6.56 (1H, d, J = 8.8 
Hz, H-5); 3.80 (3H, s, -OCH3); 3.72 (3H, s, -OCH3); 3.68 (3H, s, -OCH3); 4.01 
(1H, s, CH2-benzyl); 7.22 (2H, d, J = 7.0 Hz); 7.18 (2H, t, J = 7.6Hz); 7.09 
(1H, t, J = 7.6Hz). HRMS (ESI): m/z [M +Na] + calcd. for C16H18O3Na
+: 
281.1148, found: 281.1154. 
(54-R5) 1H-NMR (CDCl3): 6.76 (1H, d, J = 8.8 Hz, H-6); 6.57 (1H, d, J = 8.8 
Hz, H-5); 3.80 (3H, s, -OCH3); 3.72 (3H, s, -OCH3); 3.70 (3H, s, -OCH3); 3.99 
(1H, s, CH2-benzyl); 7.19 (2H, s); 7.17 (2H, s). HRMS (ESI): m/z [M +Na]
 + 
calcd. for C16H17ClO3Na
+: 315.0758, found: 315.0770. 
(54-R6) 1H-NMR (CDCl3): 6.85 (1H, d, J = 8.8 Hz, H-6); 6.65 (1H, d, J = 8.8 
Hz, H-5); 3.88 (3H, s, -OCH3); 3.85 (3H, s, -OCH3); 3.80 (3H, s, -OCH3); 4.20 
(1H, s, CH2-benzyl); 7.57 (2H, d, J = 8.0 Hz); 7.48 (2H, d, J = 8.0 Hz). HRMS 
(ESI): m/z [M +Na] + calcd. for C17H17F3O3Na
+: 349.1022, found: 281.1004. 
 
Synthesis of compounds 55-R4, 55-R5 and 55-R6. 2.2 mmol of each compound 
(570 mg of 54-R4, 643 mg of 54-R5, 717 mg of 54-R6) dissolved in 90 mL of 
acetonitrile were added dropwise to a solution of CAN (6.0 g, 11.0 mmol) in 
water (110 mL) at rt. The mixture was stirred for 30 minutes at room 
temperature (the end of the reaction was checked by TLC, eluent: chloroform/ 
EtOAc 7:3). The orange liquid was then poured into 100 mL of cold water and 
extracted three times with ethyl acetate. The combined organic layers were 
washed with brine, dried over sodium sulfate, and filtered. The solvent removal 
under reduced pressure afforded 55-R4 (324 mg ,65%), 55-R5 (372 mg ,64%), 
55-R6 (427 mg, 65%), sufficiently pure for the following reaction. (55-R4) 1H-
NMR (CDCl3): 6.66 (1H, d, J = 10.0 Hz, H-6); 6.57 (1H, d, J = 10.0 Hz, H-5); 
4.02 (3H, s, -OCH3); 3.77 (1H, s, CH2-benzyl); 7.25 (2H, d, J = 7.0 Hz); 7.23 
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(2H, t, J = 7.6Hz); 7.16 (1H, t, J = 7.6Hz). HRMS (ESI): m/z [M +Na] + calcd. 
for C14H12O3Na
+: 251.0679, found: 251.0689. 
(55-R5) 1H-NMR (CDCl3): 6.66 (1H, d, J = 10.0 Hz, H-6); 6.57 (1H, d, J = 
10.0 Hz, H-5); 4.04 (3H, s, -OCH3); 3.71 (1H, s, CH2-benzyl); 7.19 (2H, d, J = 
8.5 Hz); 7.17 (2H, d, J = 8.5 Hz); HRMS (ESI): m/z [M +Na] + calcd. for 
C14H11ClO3Na
+: 315.0758, found: 315.0770. 
(55-R6) 1H-NMR (CDCl3): 6.67 (1H, d, J = 10.0 Hz, H-6); 6.59 (1H, d, J = 
10.0 Hz, H-5); 4.06 (3H, s, -OCH3); 3.80 (1H, s, CH2-benzyl); 7.50 (2H, d, J = 
8.0 Hz); 7.36 (1H, d, J = 8.0Hz). HRMS (ESI): m/z [M +Na] + calcd. for 
C15H11F3O3Na
+: 319.0553, found: 319.0545. 
 
Synthesis of compounds 56-61. 1.42 mmol of each quinone (324 mg of 55-R4, 
372 mg of 55-R5, 420 mg of 55-R6) were dissolved in 26 mL of a mixture of 
EtOH/CH3CN 1:1 and heated in a water bath under stirring; then, a solution of 
hypotaurine (155 mg, 1.42 mmol) in 2 mL of water and a catalytic amount of 
salcomine were added in portions. The mixture was stirred for 24 h at room 
temperature. The yellow solution became orange/red. Most of the ethanol was 
removed in vacuo and the residue was poured into water. The mixture was 
extracted with ether (three times) and the organic phase was washed with brine, 
dried over sodium sulfate, and filtered. Solvent removal gave residues 
containing a mixture of the isomers 56/57 (from 55-R4, 175 mg, 37 % yield), 
58/59 (from 55-R5, 181 mg, 35 % yield) as well as of compounds 60/61 (from 
55-R6, 213 mg, 37 % yield); they were separated as reported below. 
 
Separation of crude mixtures of 56-61 isomers. Separation of isomers 56/57 
mixture (175 mg) was achieved by HPLC on a SiO2 column (Luna 5µm, 250 x 
4.60 mm) eluting with EtOAc/hexane 6:4 (v/v) and afforded pure compounds 
56 (14 mg) and 57 (56 mg). Mixture of isomers 58/59 (181 mg), as well as that 
of 60/61 (213 mg), were separated in the same conditions and yielded pure 
compounds 58 (10 mg), 59 (42 mg), 60 (11 mg), and 61 (49 mg). 
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(56): HPLC EtOAc/hexane 6:4 (v/v), (tR): 14 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.5. HRMS (ESI): m/z [M +Na] + calcd. for 
C16H15NO5SNa
+: 356.0563, found: 356.0565. 
(57): HPLC EtOAc/hexane 6:4 (v/v), (tR): 27 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.5. HRMS (ESI): m/z [M +Na] + calcd. for 
C16H15NO5SNa
+: 356.0563, found: 356.0565. 
(58) HPLC: EtOAc/hexane 6:4 (v/v), (tR): 7 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.6. HRMS (ESI): m/z [M +Na] + calcd. for 
C16H14ClNO5SNa
+: 390.0173, found: 390.0169. 
(59) HPLC: EtOAc/hexane 6:4 (v/v), (tR): 14 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.6. HRMS (ESI): m/z [M +Na] + calcd. for 
C16H14ClNO5SNa
 +: 390.0173, found: 390.0169. 
(60) HPLC: EtOAc/hexane 6:4 (v/v), (tR): 11 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.6 HRMS (ESI): m/z [M-H]- calcd. for 
C17H13F3NO5S: 400.0461, found: 400.0491. 
(61) HPLC: EtOAc/hexane 6:4 (v/v), (tR): 21 min (single peak). 
1H and 13C 
NMR data are reported in Table 5.6. HRMS (ESI): m/z [M-H]- calcd. for 
C17H13F3NO5S: 400.0461, found: 400.0492. 
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CHAPTER 7 
 SUPPORTING DATA 
 
7.1. Mass Spectra 
 
HRESI MS spectrum of phallusiasterol C (6) 
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Esterificazione 21_9_16 MPA Fr6HR+ #19 RT: 0.14 AV: 1 NL: 1.21E8
T: FTMS + c ESI Full ms [150.00-1500.00]
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HRESI MS spectrum of compound 21  
 
 
 
 
 
 
 
 
 
HRESI MS spectrum of compound 22  
 
 
 
Esterificazione 21_9_16 MPA Fr6HR+ #71 RT: 0.54 AV: 1 NL: 1.47E8
T: FTMS + c ESI Full ms [150.00-1500.00]
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HRESI MS spectrum of compound 23  
Esterificazione 21_9_16 MPA Fr6HR+ #6 RT: 0.04 AV: 1 NL: 1.21E8
T: FTMS + c ESI Full ms [150.00-1500.00]
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HRESI MS spectrum of compound 24  
 
 
 
Esterificazione 21_9_16 MPA Fr6HR+ II volta #684 RT: 6.23 AV: 1 NL: 1.02E7
T: FTMS + c ESI Full ms [530.00-1500.00]
700 800 900 1000 1100 1200 1300 1400 1500
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
713.3688
729.3426
1403.7489
1117.7715792.5078691.3874
750.4607
1419.7239
1358.99851061.7086849.3451 1301.9663907.8560 963.8529 1217.7998
 
 
106 
 
HRESI MS spectrum of compound 25 
 
Ciclizzazione Fr8  28_11_16 HR+2 #32 RT: 0.44 AV: 1 NL: 5.03E7
T: FTMS + c ESI Full ms [100.00-1000.00]
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HRESI MS spectrum of compound 26 
 
 
Ciclizzazione Fr7  28_11_16 HR+ diluito buono #228 RT: 3.20 AV: 1 NL: 6.87E7
T: FTMS + c ESI Full ms [100.00-1000.00]
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ESI MS spectrum of compound 39 
N2x1-neg #1726 RT: 4.07 AV: 1 NL: 7.43E4
T: ITMS - c ESI Full ms [100.00-1000.00]
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ESI MS spectrum of compound 40 
 
 
A2x1  A2 ossid HPLC 30_5_14 Fr4 pos #52 RT: 0.10 AV: 1 NL: 3.44E6
T: ITMS + c ESI Full ms [150.00-800.00]
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ESI MS spectrum of compound 41 
 
B2x1 pos 5_6_14 #185 RT: 0.37 AV: 1 NL: 3.44E6
T: ITMS + c ESI Full ms [200.00-1000.00]
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ESI MS spectrum of compound 42 
 
 
 
N2x1-neg #1554 RT: 3.66 AV: 1 NL: 7.98E4
T: ITMS - c ESI Full ms [100.00-1000.00]
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HRESI MS spectrum of compound 46  
 
 
Isobutile D1 HR+_160912143555 #114 RT: 0.87 AV: 1 NL: 3.41E7
T: FTMS + c ESI Full ms [100.00-1000.00]
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HRESI MS spectrum of compound 47  
 
 
Isobutile D2 HR+_160912143555 #53 RT: 0.40 AV: 1 NL: 6.57E7
T: FTMS + c ESI Full ms [100.00-700.00]
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HRESI MS spectrum of compound 48  
 
Isobutile D2 HR+_160912143555 #34 RT: 0.26 AV: 1 NL: 1.81E7
T: FTMS + c ESI Full ms [100.00-700.00]
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HRESI MS spectrum of compound 49 
 
 
Isobutile D2 HR+_160912143555 #21 RT: 0.16 AV: 1 NL: 1.75E7
T: FTMS + c ESI Full ms [100.00-700.00]
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HRESI MS spectrum of compound 50 
 
Reaz cond (cicloesile) HPL C6_05_15Fr3+ #37 RT: 0.28 AV: 1 NL: 1.77E7
T: FTMS + c ESI Full ms [100.00-1500.00]
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HRESI MS spectrum of compound 51 
 
 
Reaz cond (cicloesile) HPL C6_05_15Fr5+II volta #1 RT: 0.00 AV: 1 NL: 3.85E6
T: FTMS + c ESI Full ms [95.00-850.00]
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HRESI MS spectrum of compound 56 
 
Reaz cond (benzile) HPL C8_06_15Fr7+ #1 RT: 0.00 AV: 1 NL: 3.42E7
T: FTMS + c ESI Full ms [95.00-850.00]
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HRESI MS spectrum of compound 57 
 
Reaz cond(benzile)HPLC 8_6_15 Fr9+ #52 RT: 0.40 AV: 1 NL: 5.70E7
T: FTMS + c ESI Full ms [95.00-850.00]
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HRESI MS spectrum of compound 58 
 
BzCl HPLC 4_7_16 Fr5 HR+ #75 RT: 1.07 AV: 1 NL: 1.08E7
T: FTMS + c ESI Full ms [325.00-1000.00]
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HRESI MS spectrum of compound 59 
 
BzCl HPLC 4_7_16 Fr5 HR+ #84 RT: 1.19 AV: 1 NL: 1.09E7
T: FTMS + c ESI Full ms [325.00-1000.00]
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HRESI MS spectrum of compound 60 
 
Cond CF3 HPLC 29_9_16 Fr5 HR-_161011121751 #29 RT: 0.77 AV: 1 NL: 2.57E6
T: FTMS - c ESI Full ms [200.00-1000.00]
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HRESI MS spectrum of compound 61 
 
Cond CF3 HPLC 29_9_16 Fr5 HR-_161011121751 #26 RT: 0.68 AV: 1 NL: 3.17E6
T: FTMS - c ESI Full ms [200.00-1000.00]
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7.2. NMR Spectra 
1H-NMR CD3OD of compound 6 
 
 
13C-NMR CD3OD of compound 6 
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COSY of compound 6 (CD3OD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HMBC of compound 6 (CD3OD 
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ROESY of compound 6 (CD3OD) 
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1H NMR of compound (18) in CDCl3 
13C NMR of compound (18) in CDCl3 
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1H NMR of compound (rac-19) in CD3OD 
13C NMR of compound (rac-19) in CD3OD 
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1H NMR of compound (rac-20) in CD3OD 
13C NMR of compound (rac-20) in CD3OD 
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1H NMR of compound (21) in CDCl3 
1H NMR of compound (22) in CDCl3 
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1H NMR of compound (23) in CDCl3 
1H NMR of compound (24) in CDCl3 
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1H NMR of compound (25) in CDCl3 
HSQC of compound 25 in CDCl3 
124 
 
 
 
 
 
 
 
 
 
ROESY of compound 25 in CDCl3 
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1H NMR of compound 26 in CDCl3 
HSQC of compound 26 in CDCl3 
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ROESY of compound 26 in CDCl3 
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1H NMR of compound 39in CD3OD 
13C NMR of compound 39 in CD3OD 
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1H NMR of compound 40 in CD3OD 
13C NMR of compound 40 in CD3OD 
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1H NMR of compound 41 in DMSO-d6 
13C NMR of compound 41 in DMSO-d6 
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1H NMR of compound 42 in CD3OD 
13C NMR of compound 42 in CD3OD 
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1H NMR of compound 46 in CDCl3 
1H NMR of compound 47 in CDCl3 
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1H NMR of compound 48 in CDCl3 
1H NMR of compound 49 in CDCl3 
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1H NMR of compound 50 in CDCl3 
1H NMR of compound 51 in CDCl3 
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1H NMR of compound 56 in CDCl3 
1H NMR of compound 57 in CDCl3 
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1H NMR of compound 58 in CDCl3 
1H NMR of compound 59 in CDCl3 
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1H NMR of compound 60 in CDCl3 
1H NMR of compound 61 in CDCl3 
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